

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2007 (13.12.2007)

PCT

(10) International Publication Number
WO 2007/143526 A2

(51) International Patent Classification:
A61K 31/4745 (2006.01)

(21) International Application Number:
PCT/US2007/070181

(22) International Filing Date: 1 June 2007 (01.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/803,927 5 June 2006 (05.06.2006) US

(71) Applicant (for all designated States except US): **COLEY PHARMACEUTICAL GROUP, INC.** [US/US]; 93 Worcester Street, Suite 101, Wellesley, MA 02481 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DELLARIA, Joseph F. Jr.** [US/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US). **MOSER, William H.** [US/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US). **RADMER, Matthew R.** [US/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US). **KSHIRSAGAR, Tushar A.** [IN/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US). **HEPPNER, Philip D.** [US/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US).

(74) Agents: **GATES, Edward, R.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED TETRAHYDROIMIDAZONAPHTHYRIDINES AND METHODS

(57) Abstract: 6,7,8,9-Tetrahydro-1H-imidazo[4,5-c]naphthyridines with a substituent at the 6-, 7-, 8-, or 9-position nitrogen atom, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

WO 2007/143526 A2

SUBSTITUTED TETRAHYDROIMIDAZONAPHTHYRIDINES AND METHODS

CROSS REFERENCE TO RELATED APPLICATIONS


The present invention claims priority to U.S. Provisional Application Serial No. 60/803927, filed June 05, 2006, which is incorporated herein by reference.

BACKGROUND

Certain compounds have been found to be useful as immune response modifiers (IRMs), rendering them useful in the treatment of a variety of disorders. However, there continues to be interest in and a need for compounds that have the ability to modulate the immune response, by induction of cytokine biosynthesis or other means.


SUMMARY OF THE INVENTION

The present invention provides a new class of compounds that are useful in inducing cytokine biosynthesis in animals. Examples of such compounds include certain substituted 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridin-4-amines of the following Formulas I, II, III, and IV:



wherein R, R₁, R₂, R₃, and n are as defined below; and pharmaceutically acceptable salts thereof.

Examples of such compounds also include the following Formulas V, VI, VII, and VIII, which are prodrugs:



wherein R, R₁, R₂, R₃, G, and n are as defined below; and pharmaceutically acceptable salts thereof.

The compounds or salts of Formulas I, II, III, IV, V, VI, VII, and VIII are useful as IRMs due to their ability to modulate cytokine biosynthesis (e.g., induce the biosynthesis or production of one or more cytokines) and otherwise modulate the immune response when administered to animals. The ability to modulate cytokine biosynthesis makes the compounds useful in the treatment of a variety of conditions such as viral diseases and neoplastic diseases that are responsive to such changes in the immune response.

In another aspect, the present invention also provides pharmaceutical compositions containing the compounds of Formulas I, II, III, IV, V, VI, VII, and/or VIII.

In another aspect of the present invention provides methods of inducing cytokine biosynthesis in animal cells, treating a viral disease in an animal, and/or treating a neoplastic disease in an animal by administering to the animal one or more compounds of the Formulas I, II, III, IV, V, VI, VII, and VIII, and/or pharmaceutically acceptable salts thereof.

In another aspect, the invention provides methods of synthesizing the compounds of Formulas I, II, III, IV, V, VI, VII, and VIII and intermediate compounds useful in the synthesis of these compounds.


As used herein, "a", "an", "the", "at least one", and "one or more" are used interchangeably.


The terms "comprising" and variations thereof do not have a limiting meaning where these terms appear in the description and claims.

5 The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The description that follows more particularly exemplifies illustrative embodiments. Guidance is also provided herein through lists of examples, which can be used in various combinations. In each instance, the recited list serves only as a representative group and should not be
10 interpreted as an exclusive list.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS OF THE INVENTION

15 The present invention provides compounds of the following Formulas I through VIII:






VIII

wherein R, R₁, R₂, R₃, G, and n are as defined below; and pharmaceutically acceptable salts thereof.

- 5 In one embodiment, the present invention provides a compound selected from the group consisting of Formulas I, II, III, and IV:




10

wherein:


R₃ is selected from the group consisting of:

-Q-R₄,



15

-Z-Ar,



-X-Y-R₄,

-X-R₅,

-alkylene-CH(CH₂-OH)-OH,

-alkylene-CH(CH₂CH₂-OH)-OH, and

-(alkylene)₀₋₁-CH(CH₂OH)₂;

Q is selected from the group consisting of -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-,
-C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-;

5 Z is selected from the group consisting of a bond, alkylene, alkenylene, and
alkynylene, wherein the alkylene, alkenylene, and alkynylene groups are optionally
interrupted by one or more -O- groups;

Ar is selected from the group consisting of aryl and heteroaryl each of which is
unsubstituted or substituted by one or more substituents independently selected from the
10 group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, hydroxyalkyl, cyano, amino, alkylamino, and dialkylamino;

D is CH or N; with the proviso that when D is N, then Q is -C(R₆)- or -S(O)₂-;

E is selected from the group consisting of -O-, -C(O)-, -S(O)₀₋₂-, and -N(Q₁-R₄)-;

15 R is selected from the group consisting of alkyl, alkoxy, fluoro, hydroxy, and
trifluoromethyl;

n is 0, 1, or 2;

R₁ is selected from the group consisting of:

-R₄,

-X-R₄,

20 -X-Y-R₄,

-X-Y-X-Y-R₄,

-X-R₅,

-N(R₁')-Q₁-R₄,



-D'-X₁-Y₁-R₄, and

25 -D'-X₁-R_{5a};


D' is selected from the group consisting of -N(R₁')- and -O-;

R₁' is selected from the group consisting of hydrogen, C₁₋₂₀ alkyl,
hydroxyC₂₋₂₀ alkylenyl, and alkoxyC₂₋₂₀ alkylenyl;

X₁ is C₂₋₂₀ alkylene with the proviso that when Y₁ is -C(R₆)-N(R₈)- or

30 , or R_{5a} is , then X₁ is C₁₋₂₀ alkylene;

Y₁ is selected from the group consisting of -O-, -S(O)_{0.2-}, -S(O)₂-N(R₈)-,

-N(R₈)-Q₁-, -C(R₆)-N(R₈)-, -O-C(R₆)-N(R₈)-, and  ;
R_{5a} is selected from the group consisting of:

$$\begin{array}{c} \text{---N---C(R}_6\text{)} \\ | \\ \text{(R}_7\text{)} \end{array}, \quad \begin{array}{c} \text{---N---S(O)}_2 \\ | \\ \text{(R}_7\text{)} \end{array}, \text{ and } \begin{array}{c} \text{---V---N} \begin{array}{l} \text{(CH}_2\text{)}_a \\ \text{(CH}_2\text{)}_b \end{array} \text{A} \end{array};$$

5 R₂ is selected from the group consisting of:






-R₄,
-X-R₄,
-X-Y-R₄,
-X-R₅,
10 -OH,
-NH₂, and
-NH-O₂-R₄;

X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;


Y is selected from the group consisting of:

20

-O-,
-S(O)₀₋₂-,
-S(O)₂-N(R₈)-,
-C(R₆)-,
-C(R₆)-O-,
-O-C(R₆)-,
-O-C(O)-O-,
25 -N(R₈)-Q₁-,
-C(R₆)-N(R₈)-,
-O-C(R₆)-N(R₈)-,
-C(R₆)-N(OR₉)-,
-O-N(R₈)-Q₁-,



, and




;

10 R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected

15 from the group consisting of alkyl; alkoxy; hydroxyalkyl; haloalkyl; haloalkoxy; halogen; nitro; hydroxy; mercapto; cyano; aryl; aryloxy; arylalkyleneoxy; heteroaryl; heteroaryloxy; heteroarylalkyleneoxy; heterocyclyl; amino; alkylamino; dialkylamino; (dialkylamino)alkyleneoxy; and, in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

20 R_5 is selected from the group consisting of:



R₆ is selected from the group consisting of =O and =S;

R₇ is C₂₋₇ alkylene;

5 R_{8a} is selected from the group consisting of hydrogen and C₁₋₄ alkyl;

R₈ is selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxyalkylenyl, alkoxyalkylenyl, arylalkylenyl, and heteroarylalkylenyl;

R₉ is selected from the group consisting of hydrogen and alkyl;

R₁₀ is C₃₋₈ alkylene;

10 A is selected from the group consisting of -CH₂-, -O-, -C(O)-, -S(O)₀₋₂-, and -N(-Q₁-R₄)-

A' is selected from the group consisting of -O-, -S(O)₀₋₂-, -N(-Q₁-R₄)-, and -CH₂-;

Q₁ is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-


15 Q₂ is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R_{8a})-W-, -S(O)₂-N(R_{8a})-, and -C(R₆)-O-

V is selected from the group consisting of a bond, -C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-;

W is selected from the group consisting of a bond, -C(O)-, and -S(O)₂-; and

20 a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7; or a pharmaceutically acceptable salt thereof.

In another embodiment, the present invention provides a compound selected from the group consisting of the Formulas V, VI, VII, and VIII, which are prodrugs:



5 wherein:

G is selected from the group consisting of:

- C(O)-R',
- α -aminoacyl,
- α -aminoacyl- α -aminoacyl,
- 10 -C(O)-O-R',
- C(O)-N(R'')R',
- C(=NY')-R',
- CH(OH)-C(O)-OY',
- CH(OC₁₋₄ alkyl)Y₀,
- 15 -CH₂Y₂, and
- CH(CH₃)Y₂;

R' and R'' are independently selected from the group consisting of C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, phenyl, benzyl, and 2-phenylethyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting

20 of halogen, hydroxy, nitro, cyano, carboxy, C₁₋₆ alkyl, C₁₋₄ alkoxy, aryl, heteroaryl, aryl-C₁₋₄ alkylenyl, heteroaryl-C₁₋₄ alkylenyl, halo-C₁₋₄ alkylenyl, halo-C₁₋₄ alkoxy, -O-C(O)-CH₃, -C(O)-O-CH₃, -C(O)-NH₂, -O-CH₂-C(O)-NH₂, -NH₂, and -S(O)₂-NH₂, with the proviso that R'' can also be hydrogen;

α -aminoacyl is an α -aminoacyl group derived from an α -amino acid selected from the group consisting of racemic, D-, and L-amino acids;


Y' is selected from the group consisting of hydrogen, C₁₋₆ alkyl, and benzyl;

Y₀ is selected from the group consisting of C₁₋₆ alkyl, carboxy-C₁₋₆ alkylenyl, amino-C₁₋₄ alkylenyl, mono-*N*-C₁₋₆ alkylamino-C₁₋₄ alkylenyl, and di-*N,N*-C₁₋₆ alkylamino-C₁₋₄ alkylenyl;

Y₂ is selected from the group consisting of mono-*N*-C₁₋₆ alkylamino, di-*N,N*-C₁₋₆ alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and 4-C₁₋₄ alkylpiperazin-1-yl; and

R₃, R, R₁, R₂, and n are defined as in Formulas I, II, III, and IV above; or a pharmaceutically acceptable salt thereof.


For certain embodiments, the compound selected from the group consisting of the Formulas I, II, III, and IV is of the Formula II:



II

wherein R₃, R, R₁, R₂, and n are defined as in Formulas I, II, III, and IV above; or a pharmaceutically acceptable salt thereof.

For certain embodiments, the compound selected from the group consisting of the Formulas I, II, III, and IV is of the Formula III:




III

wherein R₃, R, R₁, R₂, and n are defined as in Formulas I, II, III, and IV above; or a pharmaceutically acceptable salt thereof.

For certain embodiments of the compounds of Formulas I through IV, the

-NH₂ group can be replaced by an -NH-G group, as shown in the compounds of Formulas V through VIII, to form prodrugs.

For certain embodiments, the compound selected from the group consisting of the Formulas V, VI, VII, and VIII is of the Formula VI:




VI

wherein R₃, R, R₁, R₂, and n are defined as in Formulas I, II, III, and IV above; and

G is defined as in Formulas V, VI, VII, and VIII above;

or a pharmaceutically acceptable salt thereof.

For certain embodiments, the compound selected from the group consisting of the Formulas V, VI, VII, and VIII is of the Formula VII:



VII

wherein R₃, R, R₁, R₂, and n are defined as in Formulas I, II, III, and IV above; and

G is defined as in Formulas V, VI, VII, and VIII above;

or a pharmaceutically acceptable salt thereof.

For any of the compounds presented herein, each one of the following variables (e.g., R₁, R₂, R₃, G, R₄, Q, Q₁, Q₂, Z, X, X₁, Y, Y₁, A, and so on) in any of its

embodiments can be combined with any one or more of the other variables in any of their embodiments and associated with any one of the formulas described herein, as would be understood by one of skill in the art. Each of the resulting combinations of variables is an embodiment of the present invention.

For certain embodiments, e.g., of Formulas V, VI, VII, and VIII, G is selected from the group consisting of -C(O)-R', α -aminoacyl, α -aminoacyl- α -aminoacyl, -C(O)-O-R', -C(O)-N(R'')R', -C(=NY')-R', -CH(OH)-C(O)-OY', -CH(OC₁₋₄ alkyl)Y₀, -CH₂Y₂, and -CH(CH₃)Y₂. For certain of these embodiments, R' and R'' are independently
 5 selected from the group consisting of C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, phenyl, benzyl, and 2-phenylethyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, nitro, cyano, carboxy, C₁₋₆ alkyl, C₁₋₄ alkoxy, aryl, heteroaryl, aryl-C₁₋₄ alkylenyl, heteroaryl-C₁₋₄ alkylenyl, halo-C₁₋₄ alkylenyl, halo-C₁₋₄ alkoxy, -O-C(O)-CH₃,
 10 -C(O)-O-CH₃, -C(O)-NH₂, -O-CH₂-C(O)-NH₂, -NH₂, and -S(O)₂-NH₂, with the proviso that R'' can also be hydrogen;

α -aminoacyl is an α -aminoacyl group derived from an α -amino acid selected from the group consisting of racemic, D-, and L-amino acids;

Y' is selected from the group consisting of hydrogen, C₁₋₆ alkyl, and benzyl;

15 Y₀ is selected from the group consisting of C₁₋₆ alkyl, carboxy-C₁₋₆ alkylenyl, amino-C₁₋₄ alkylenyl, mono-*N*-C₁₋₆ alkylamino-C₁₋₄ alkylenyl, and di-*N,N*-C₁₋₆ alkylamino-C₁₋₄ alkylenyl; and

Y₂ is selected from the group consisting of mono-*N*-C₁₋₆ alkylamino, di-*N,N*-C₁₋₆ alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and
 20 4-C₁₋₄ alkylpiperazin-1-yl.

For certain embodiments, including any one of the above embodiments of Formulas V, VI, VII, and VIII, G is selected from the group consisting of -C(O)-R', α -aminoacyl, and -C(O)-O-R'.

For certain embodiments, including any one of the above embodiments of Formula
 25 V, VI, VII, and VIII, G is selected from the group consisting of -C(O)-R', α -amino-C₂₋₁₁ acyl, and -C(O)-O-R'. For certain of these embodiments, α -amino-C₂₋₁₁ acyl includes α -amino acids containing a total of at least 2 carbon atoms and a total of up to 11 carbon atoms, and may also include one or more heteroatoms selected from the group consisting of O, S, and N. For certain of these embodiments, R' is C₁₋₁₀ alkyl.

30 For certain embodiments, including any one of the above embodiments which include an α -aminoacyl group, α -aminoacyl is an α -aminoacyl group derived from a

naturally occurring α -amino acid selected from the group consisting of racemic, D-, and L-amino acids.


For certain embodiments, including any one of the above embodiments which include an α -aminoacyl group, α -aminoacyl is an α -aminoacyl group derived from an α -amino acid found in proteins, wherein the the α -amino acid is selected from the group consisting of racemic, D-, and L-amino acids.


For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R is selected from the group consisting of alkyl, alkoxy, fluoro, hydroxy, and trifluoromethyl.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, n is 0, 1, or 2. For certain of these embodiments, n is 1. Alternatively, for certain of these embodiments, n is 0.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R₁ is selected from the group consisting of -R₄, -X-R₄, -X-Y-R₄, -X-Y-X-Y-R₄, -X-R₅, -N(R₁')-Q₁-R₄, -D'-X₁-Y₁-R₄, and -D'-X₁-R_{5a}.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R₁ is selected from the group consisting of -R₄, -X-R₄, -X-Y-R₄, and -X-R₅. For certain of these embodiments, R₁ is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, dihydroxyalkyl, -X-Y-R₄, -X-R₅, and heterocyclalkylenyl wherein the heterocycl of the heterocyclalkylenyl group is optionally substituted by one or more alkyl groups; wherein X is alkylene; Y is -N(R₈)-C(O)-, -N(R₈)-S(O)₂-, -N(R₈)-C(R₆)-N(R₈)-,

-N(R₈)-C(R₆)-O-, -C(O)-, -S(O)₂-, or ; R₄ is alkyl, aryl, heteroaryl, arylalkylenyl, heteroarylalkylenyl, or arylalkenylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocycl, cyano, alkoxy, and dialkylamino; and R₅ is

. For certain of these embodiments, X is C₂₋₆ alkylene.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R₁ is selected from the group consisting of 2-hydroxy-2-methylpropyl, 2-methylpropyl, 2,3-dihydroxypropyl, 4-[(methylsulfonyl)amino]butyl, 2-methyl-2-[(methylsulfonyl)amino]propyl, 2-(acetylamino)-2-methylpropyl, 2-[[[(isopropylamino)carbonyl]amino]-2-methylpropyl, 4-[[[(isopropylamino)carbonyl]amino]butyl, 4-(1,1-dioxidoisothiazolidin-2-yl)butyl, tetrahydro-2H-pyran-4-ylmethyl, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl, 2,2-dimethyl-4-oxopentyl, (1-hydroxycyclobutyl)methyl, (1-hydroxycyclopentyl)methyl, and (1-hydroxycyclohexyl)methyl.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R₁ is -R₄, -X-R₄, -X-Y-R₄, or -X-R₅, R₁ is selected from the group consisting of -N(R₁')-Q₁-R₄, -D'-X₁-Y₁-R₄, and -D'-X₁-R_{5a}. For certain of these embodiments, D' is N(R₁'). For certain of these embodiments, R₁ is -N(R₁')-Q₁-R₄. Alternatively, for certain of these embodiments, R₁ is -N(R₁')-X₁-Y₁-R₄. Alternatively, for certain of these embodiments, R₁ is -N(R₁')-X₁-R_{5a}. Alternatively, for certain embodiments where R₁ is -N(R₁')-Q₁-R₄, -D'-X₁-Y₁-R₄, or -D'-X₁-R_{5a}, R₁ is -O-X₁-Y₁-R₄ or -O-X₁-R_{5a}.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R₂ is selected from the group consisting of -R₄, -X-R₄, -X-Y-R₄, -X-R₅, -OH, -NH₂, and -NH-Q₂-R₄. For certain of these embodiments, R₂ is selected from the group consisting of -R₄, -X-R₄, -X-Y-R₄, and -X-R₅. Alternatively, for certain of these embodiments, R₂ is -OH, -NH₂, or -NH-Q₂-R₄.



For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R₂ is -OH, -NH₂, or -NH-Q₂-R₄, R₂ is -R₄. For certain of these embodiments, R₂ is hydrogen, alkyl, alkoxyalkylenyl, or hydroxyalkylenyl. For certain of these embodiments, R₂ is selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, 2-methoxyethyl, 2-hydroxyethyl, ethoxymethyl, and hydroxymethyl.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R₂ is -R₄, -X-R₄, -X-Y-R₄, or -X-R₅, R₂ is -OH. For certain of these embodiments, R₁ is selected from the group consisting of pyridin-3-ylmethyl, isoxazol-5-ylmethyl, isoxazol-3-ylmethyl, [5-(4-

fluorophenyl)isoxazol-3-yl)methyl, [3-(4-fluorophenyl)isoxazol-5-yl)methyl, tetrahydro-2H-pyran-4-ylmethyl, and benzyl, wherein benzyl is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen.

5 For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R_2 is $-R_4$, $-X-R_4$, $-X-Y-R_4$, $-X-R_5$, or $-OH$, R_2 is $-NH-Q_2-R_4$. For certain of these embodiments, Q_2 is $-C(O)-$, $-S(O)_2-$, or $-C(O)-N(R_8)-$. For certain of these embodiments, $-R_4$ in $-Q_2-R_4$ is alkyl, aryl, heteroaryl, arylalkylenyl, or heteroarylalkylenyl, wherein alkyl, aryl, heteroaryl, or
10 arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, and dialkylamino. Alternatively, for certain of these embodiments, Q_2 is $-C(O)-O-$. For certain of these embodiments, R_4 in $-Q_2-R_4$ is C_{1-4} alkyl. Alternatively, for certain embodiments where R_2 is $-NH-Q_2-R_4$, Q_2 is a bond. For certain of these
15 embodiments, R_4 in $-Q_2-R_4$ is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy C_{2-4} alkylenyl, or hydroxy C_{2-4} alkylenyl.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R_3 is selected from the group consisting of


20 $-Q-R_4$, $-Q-D$  $N-Q_1-R_4$, $-Z-Ar$, $-Z$  E , $-X-Y-R_4$, $-X-R_5$,
-alkylene-CH(CH₂-OH)-OH, -alkylene-CH(CH₂CH₂-OH)-OH, and
-(alkylene)₀₋₁-CH(CH₂OH)₂.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R_3 is $-Q-R_4$. For certain of these
25 embodiments, Q is selected from the group consisting of $-C(O)-$, $-S(O)_2-$, $-C(O)-N(R_8)-$, $-C(O)-O-$, and $-S(O)_2-N(R_8)-$.


For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, R_4 in $-Q-R_4$ is selected from the group consisting of alkyl, aryl, heteroaryl, heterocyclyl, and arylalkylenyl, wherein aryl, alkyl,
30 and aryl in arylalkylenyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, and alkyl, and

wherein heterocyclyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl and oxo.


For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, Q is -C(O)- or -S(O)₂-. For certain of these
 5 embodiments, R₄ in -Q-R₄ is selected from the group consisting of:



For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where Q is -C(O)- or -S(O)₂-, Q is
 10 -C(O)-O-. For certain of these embodiments, -R₄ is selected from the group consisting of:




For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R₃ is -Q-R₄, R₃ is



For certain of these embodiments, Q is -C(O)- or -S(O)₂-. For
 15 certain of these embodiments, Q₁ in -Q₁-R₄ is -C(O)-, -S(O)₂-, or -C(O)-N(R₈)-. For certain of these embodiments, -R₄ in -Q₁-R₄ is alkyl, aryl, heteroaryl, arylalkylenyl, or heteroarylalkylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, and dialkylamino.

For certain of these embodiments, D is CH. Alternatively, for certain of these
 20 embodiments, D is N.


For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R₃ is -Q-R₄ or



R₃ is -Z-Ar. For certain of these embodiments, Z is alkylene. For
 25 certain of these embodiments, Z is C₁₋₄ alkylene. For certain of these embodiments, Ar is pyridinyl, furyl, or phenyl wherein phenyl is optionally substituted by one or more


substituents independently selected from the group consisting of halogen, alkoxy, and alkyl.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R_3 is $-Q-R_4$,




5 , or $-Z-Ar$, R_3 is $-X-Y-R_4$ or $-X-R_5$. For certain of these embodiments, X in R_3 is alkylenyl. For certain of these embodiments, X is C_{1-4} alkylenyl. For certain of these embodiments, Y in the R_3 group $-X-Y-R_4$ is selected from the group consisting of $-C(O)-$, $-S(O)_2-$, $-C(O)-O-$, and $-C(O)-N(R_8)-$. For certain of these
 10 embodiments, R_4 in the R_3 group $-X-Y-R_4$ is selected from the group consisting of alkyl, alkenyl, heterocyclyl, aryl, and arylalkylenyl, wherein aryl and aryl in arylalkylenyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, alkyl, and amino, and wherein alkyl is optionally
 substituted by one or more substituents independently selected from the group consisting of fluoro, alkoxy, and heterocyclyl. For certain of these embodiments, R_3 is $-X-Y-R_4$.

15 For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII where R_3 is $-X-Y-R_4$ or $-X-R_5$, R_5 in the R_3



For certain embodiments, including any one of the above embodiments of Formulas I, II,
 20 III, IV, V, VI, VII, and VIII where R_3 is $-X-Y-R_4$ or $-X-R_5$, except where Y is $-C(O)-$, $-S(O)_2-$, $-C(O)-O-$, or $-C(O)-N(R_8)-$, Y in the R_3 group $-X-Y-R_4$ is $-NH-Q_1-$. For certain of these embodiments, Q_1 in $-NH-Q_1-$ is $-C(O)-$, $-S(O)_2-$, or $-C(O)-N(R_8)-$. For certain of these embodiments, R_4 in $-NH-Q_1-R_4$ is selected from the group consisting of alkyl, aryl, heteroaryl, heterocyclyl, and arylalkylenyl, wherein aryl, alkyl, and aryl in arylalkylenyl
 25 are optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, and alkyl, and wherein heterocyclyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl and oxo. For certain of these embodiments, R_3 is $-X-Y-R_4$.

For certain embodiments, including any one of the above embodiments of Formulas I, II, III, IV, V, VI, VII, and VIII, except where R_3 is $-Q-R_4$,




, $-Z-Ar$, $-X-Y-R_4$, or $-X-R_5$, R_3 is $-alkylene-CH(CH_2-OH)-OH$, $-alkylene-CH(CH_2CH_2-OH)-OH$, or $-(alkylene)_{0-1}-CH(CH_2OH)_2$. For certain of these
 5 embodiments, R_3 is $-CH(CH_2OH)_2$.

For certain embodiments, R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl,
 10 heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl; alkoxy; hydroxyalkyl; haloalkyl; haloalkoxy; halogen; nitro; hydroxy; mercapto; cyano; aryl; aryloxy; arylalkyleneoxy; heteroaryl; heteroaryloxy; heteroarylalkyleneoxy; heterocyclyl; amino;
 15 alkylamino; dialkylamino; (dialkylamino)alkyleneoxy; and, in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo.


For certain embodiments, R_4 is alkyl, aryl, heteroaryl, arylalkylenyl, heteroarylalkylenyl, or arylalkenylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group
 20 consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, and dialkylamino.

For certain embodiments, R_4 is alkyl, aryl, heteroaryl, heterocyclyl, or arylalkylenyl, wherein aryl, alkyl, and aryl in arylalkylenyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, and alkyl, and wherein heterocyclyl is optionally substituted by one or more
 25 substituents independently selected from the group consisting of alkyl and oxo.

For certain embodiments, R_4 is selected from the group consisting of:



For certain embodiments, R_4 is selected from the group consisting of:



5 For certain embodiments, R_4 is alkyl, aryl, heteroaryl, arylalkylenyl, or heteroarylalkylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, and dialkylamino.

For certain embodiments, R_4 is alkyl, alkenyl, heterocyclyl, aryl, or arylalkylenyl, wherein aryl and aryl in arylalkylenyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, alkyl, and amino, and wherein alkyl is optionally substituted by one or more substituents independently selected from the group consisting of fluoro, alkoxy, and heterocyclyl.

For certain embodiments, R_4 is selected from the group consisting of alkyl, aryl, heteroaryl, heterocyclyl, and arylalkylenyl wherein alkyl, aryl, and heteroaryl are each unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, and halogen.

For certain embodiments, R_4 is selected from the group consisting of alkyl, aryl, arylalkylenyl, and heteroarylalkylenyl wherein alkyl is optionally substituted by one or more substituents independently selected from the group consisting of alkoxy and hydroxy.

For certain embodiments, R_4 is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, and hydroxyalkylenyl.

For certain embodiments, R_4 is hydrogen, alkyl, alkoxyalkylenyl, or hydroxyalkylenyl.

For certain embodiments, R_4 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy C_{2-4} alkylenyl, or hydroxy C_{2-4} alkylenyl.


For certain embodiments, R_4 is C_{1-6} alkyl.

For certain embodiments, R_4 is C_{1-4} alkyl.


For certain embodiments, R_4 is selected from the group consisting of pyridin-3-ylmethyl, isoxazol-5-ylmethyl, isoxazol-3-ylmethyl, tetrahydro-2H-pyran-4-ylmethyl, and benzyl, wherein benzyl is unsubstituted or substituted by one or more substituents
 5 independently selected from the group consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen.

For certain embodiments, R_4 is 4-fluorophenyl.


For certain embodiments, R_5 is selected from the group consisting of:




For certain embodiments, R_5 is selected from the group consisting of:



For certain embodiments, R_5 is



For certain embodiments, R_{5a} is selected from the group consisting of:



For certain embodiments, R_{5a} is

For certain embodiments, R_6 is selected from the group consisting of =O and =S.

For certain embodiments, R_6 is =O.

20 For certain embodiments, R_6 is =S.

For certain embodiments, R_7 is C_{2-7} alkylene.

For certain embodiments, R_7 is C_{2-4} alkylene.

For certain embodiments, R₇ is ethylene.

For certain embodiments, R_{8a} is selected from the group consisting of hydrogen and C₁₋₄ alkyl.

For certain embodiments, R_{8a} is hydrogen.

5 For certain embodiments, R_{8a} is C₁₋₄ alkyl.

For certain embodiments, R₈ is selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxyalkylenyl, alkoxyalkylenyl, arylalkylenyl, and heteroarylalkylenyl.

For certain embodiments, R₈ is hydrogen, C₁₋₁₀ alkyl, or hydroxy-C₁₋₁₀ alkylenyl.

For certain embodiments, R₈ is C₁₋₁₀ alkyl or hydroxy-C₁₋₁₀ alkylenyl.

10 For certain embodiments, R₈ is hydrogen.

For certain embodiments, R₈ is C₁₋₁₀ alkyl.

For certain embodiments, R₉ is selected from the group consisting of hydrogen and alkyl.

For certain embodiments, R₁₀ is C₃₋₈ alkylene.

15 For certain embodiments, R₁₀ is C₄₋₆ alkylene.

For certain embodiments, R₁₀ is pentylene.

For certain embodiments, A is selected from the group consisting of -CH₂-, -O-, -C(O)-, -S(O)₀₋₂-, and -N(-Q₁-R₄)-.

20 For certain embodiments, A is selected from the group consisting of -CH₂-, -O-, and -N(alkyl)-.

For certain embodiments, A is -O-.

For certain embodiments, A' is selected from the group consisting of -O-, -S(O)₀₋₂-, -N(-Q₁-R₄)-, and -CH₂-.

25 For certain embodiments, Ar is selected from the group consisting of aryl and heteroaryl each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, cyano, amino, alkylamino, and dialkylamino.

30 For certain embodiments, Ar is pyridinyl, furyl, or phenyl wherein phenyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, and alkyl.

For certain embodiments, Ar is phenyl.

For certain embodiments, Ar is pyridinyl.

For certain embodiments, D is CH or N; with the proviso that when D is N, then Q is -C(R₆)- or -S(O)₂-.

For certain embodiments, D is CH.

5 For certain embodiments, D is N, and Q is -C(R₆)- or -S(O)₂-.

For certain embodiments, D' is selected from the group consisting of -N(R₁')- and -O-.

For certain embodiments, D' is -N(R₁')-.

For certain embodiments, D' is -O-.

10 For certain embodiments, E is selected from the group consisting of -O-, -C(O)-, -S(O)_{0.2}-, and -N(Q₁-R₄)-.

For certain embodiments, E is -O-.

For certain embodiments, E is -N(Q₁-R₄)-.

15 For certain embodiments, Q is selected from the group consisting of -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-.

For certain embodiments, Q is selected from the group consisting of -C(O)-, -S(O)₂-, -C(O)-N(R₈)-, -C(O)-O-, and -S(O)₂-N(R₈)-.

For certain embodiments, Q is -C(O)- or -S(O)₂-.

20 For certain embodiments, Q is -C(O)-O-.

For certain embodiments, Q₁ is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-.

25 For certain embodiments, Q₁ is selected from the group consisting of -C(O)-, -S(O)₂-, -C(R₆)-N(R₈)-, -S(O)₂-N(R₈)-, -C(O)-O-, and -C(O)-S-.

For certain embodiments, Q₁ is -C(O)-, -S(O)₂-, -C(R₆)-N(R₈)-, or -S(O)₂-N(R₈)-.

For certain embodiments, Q₁ is -C(O)-, -S(O)₂-, -C(R₆)-N(R₈)-, or -C(R₆)-O-.

For certain embodiments, Q₁ is -C(O)-, -S(O)₂-, or -C(O)-N(R₈)-.

For certain embodiments, Q₁ is -C(R₆)-.

30 For certain embodiments, Q₁ is a bond.

For certain embodiments, Q₂ is selected from the group consisting of a bond, -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R_{8a})-W-, -S(O)₂-N(R_{8a})-, and -C(R₆)-O-.

For certain embodiments, Q₂ is -C(O)-, -S(O)₂-, or -C(O)-N(R₈)-

For certain embodiments, Q₂ is -C(O)-O-

For certain embodiments, Q₂ is a bond.

For certain embodiments, R₁' is selected from the group consisting of hydrogen,
5 C₁₋₂₀ alkyl, hydroxyC₂₋₂₀ alkylenyl, and alkoxyC₂₋₂₀ alkylenyl

For certain embodiments, R₁' is hydrogen.

For certain embodiments, R₁' is C₁₋₁₀ alkyl.

For certain embodiments, V is selected from the group consisting of a bond,
-C(R₆)-, -O-C(R₆)-, -N(R₈)-C(R₆)-, and -S(O)₂-.

10 For certain embodiments, V is -N(R₈)-C(O)-. For certain embodiments, V is
-N(H)-C(O)-.

For certain embodiments, W is selected from the group consisting of a bond,
-C(O)-, and -S(O)₂-.

For certain embodiments, W is a bond.


15 For certain embodiments, X is selected from the group consisting of alkylene,
alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene,
alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene,
heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups.

For certain embodiments, X is alkylene.

20 For certain embodiments, X is C₂₋₆ alkylene.

For certain embodiments, X is C₁₋₄ alkylene. For certain embodiments, X is
methylene.

For certain embodiments, X₁ is C₂₋₂₀ alkylene with the proviso that when Y₁ is




25 C₁₋₂₀ alkylene.


For certain embodiments, X₁ is C₂₋₆ alkylene.

For certain embodiments, X₁ is C₂₋₄ alkylene.

For certain embodiments, X₁ is C₁₋₆ alkylene or C₁₋₄ alkylene, and Y₁ is




For certain embodiments, Y is selected from the group consisting of -O-, -S(O)₀₋₂-, -S(O)₂-N(R₈)-, -C(R₆)-, -C(R₆)-O-, -O-C(R₆)-, -O-C(O)-O-, -N(R₈)-Q₁-, -C(R₆)-N(R₈)-, -O-C(R₆)-N(R₈)-, -C(R₆)-N(OR₉)-, -O-N(R₈)-Q₁-, -O-N=C(R₄)-,



For certain embodiments, Y is -N(R₈)-Q₁-.

For certain embodiments, Y is -N(R₈)-C(O)-, -N(R₈)-S(O)₂-,




For certain embodiments, Y is -C(O)-, -S(O)₂-, -C(O)-O-, or -C(O)-N(R₈)-.

For certain embodiments, Y is -NH-Q₁-.

For certain embodiments, Y is selected from the group consisting of -NH-C(O)-, -NH-S(O)₂-, -NH-C(R₆)-N(R₈)-, -NH-S(O)₂-N(R₈)-, -NH-C(O)-O-, and -NH-C(O)-S-.

For certain embodiments, Y is -NH-C(O)-, -NH-S(O)₂-, or -N(H)-C(O)-N(R₈)-.

For certain embodiments, Y₁ is selected from the group consisting of -O-, -S(O)₀₋₂-, -S(O)₂-N(R₈)-, -N(R₈)-Q₁-, -C(R₆)-N(R₈)-, -O-C(R₆)-N(R₈)-, and



For certain embodiments, Y₁ is -O-, -S(O)₂-N(R₈)-, -O-C(R₆)-N(R₈)-, -C(R₆)-N(R₈)-, -N(R₈)-C(R₆)-, -N(R₈)-C(R₆)-O-, -N(R₈)-S(O)₂-, -N(R₈)-S(O)₂-N(R₈)-, or -N(R₈)-C(R₆)-N(R₈)-.

For certain embodiments, Y₁ is -N(R₈)-C(R₆)-, -N(R₈)-C(R₆)-O-, -N(R₈)-S(O)₂-,

-N(R₈)-S(O)₂-N(R₈)-, or -N(R₈)-C(R₆)-N(R₈)-.

For certain embodiments, Y₁ is -N(R₈)-C(O)-, -N(R₈)-S(O)₂-, or -N(R₈)-C(O)-N(R₈)-, and R₈ is H or C₁₋₄ alkyl.

For certain embodiments, Z is selected from the group consisting of a bond,
5 alkylene, alkenylene, and alkynylene, wherein the alkylene, alkenylene, and alkynylene groups are optionally interrupted by one or more -O- groups.

For certain embodiments, Z is alkylene.

For certain embodiments, Z is C₁₋₄ alkylene.

For certain embodiments, Z is a bond.

10 For certain embodiments, a and b are independently integers from 1 to 6 with the proviso that a + b is ≤ 7.

For certain embodiments, a and b are each independently 1, 2, or 3.

For certain embodiments, a and b are each 2.

For certain embodiments, n is 0.

15 For certain embodiments, n is 1.

For certain embodiments, n is 2.

For certain embodiments, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of any one of the above embodiments of Formulas I through VIII, and a pharmaceutically
20 acceptable carrier.

For certain embodiments, the present invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of any one of the above embodiments of Formulas I through VIII, or a pharmaceutical composition comprising an effective amount of a compound or salt of any
25 one of the above embodiments of Formulas I through VIII to the animal. For certain of these embodiments, the cytokine is selected from the group consisting of IFN-α, TNF-α, IL-6, IL-10, and IL-12. For certain of these embodiments, the cytokine is IFN-α or TNF-α. For certain of these embodiments, the cytokine is IFN-α.

For certain embodiments, the present invention provides a method of treating a
30 viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of any one of the above embodiments of Formulas I through VIII, or a

pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of any one of the above embodiments of Formulas I through VIII to the animal.

For certain embodiments, the present invention provides a method of treating a neoplastic disease in an animal comprising administering a therapeutically effective
5 amount of a compound or salt of any one of the above embodiments of Formulas I through VIII, or a pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of any one of the above embodiments of Formulas I through VIII to the animal.

As used herein, the terms "alkyl", "alkenyl", "alkynyl" and the prefix "alk-" are
10 inclusive of both straight chain and branched chain groups and of cyclic groups, e.g., cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms, and alkynyl groups containing from 2 to 20 carbon atoms. In some embodiments, these groups have a total of up to 10 carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, up to 4 carbon
15 atoms, or up to 2 carbon atoms. Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms. Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cyclohexylmethyl, adamantyl, and substituted and unsubstituted bornyl, norbornyl, and norbornenyl.

Unless otherwise specified, "alkylene", "-alkylene-", "alkenylene",
20 "-alkenylene-", "alkynylene", and "-alkynylene-" are the divalent forms of the "alkyl", "alkenyl", and "alkynyl" groups defined above. The terms "alkylenyl", "alkenylenyl", and "alkynylenyl" are used when "alkylene", "alkenylene", and "alkynylene", respectively, are substituted. For example, an arylalkylenyl group comprises an "alkylene" moiety to which
25 an aryl group is attached.

The term "haloalkyl" is inclusive of alkyl groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of other groups that include the prefix "halo-". Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.

30 The term "aryl" as used herein includes carbocyclic aromatic rings or ring systems. Examples of aryl groups include phenyl, naphthyl, biphenyl, fluorenyl and indenyl.

Unless otherwise indicated, the term "heteroatom" refers to the atoms O, S, or N.

The term "heteroaryl" includes aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N). In some embodiments, the term "heteroaryl" includes a ring or ring system that contains 2 to 12 carbon atoms, 1 to 3 rings, 1 to 4 heteroatoms, and O, S, and/or N as the heteroatoms. Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl, tetrazinyl, oxadiazolyl, thiadiazolyl, and so on.

The term "heterocyclyl" includes non-aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups. In some embodiments, the term "heterocyclyl" includes a ring or ring system that contains 2 to 12 carbon atoms, 1 to 3 rings, 1 to 4 heteroatoms, and O, S, and N as the heteroatoms. Exemplary heterocyclyl groups include pyrrolidinyl, tetrahydrofuranyl, morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, tetrahydropyranyl, quinuclidinyl, homopiperidinyl (azepanyl), 1,4-oxazepanyl, homopiperazinyl (diazepanyl), 1,3-dioxolanyl, aziridinyl, azetidiny, dihydroisoquinolin-(1*H*)-yl, octahydroisoquinolin-(1*H*)-yl, dihydroquinolin-(2*H*)-yl, octahydroquinolin-(2*H*)-yl, dihydro-1*H*-imidazolyl, 3-azabicyclo[3.2.2]non-3-yl, and the like.


The term "heterocyclyl" includes bicyclic and tricyclic heterocyclic ring systems. Such ring systems include fused and/or bridged rings and spiro rings. Fused rings can include, in addition to a saturated or partially saturated ring, an aromatic ring, for example, a benzene ring. Spiro rings include two rings joined by one spiro atom and three rings joined by two spiro atoms.

When "heterocyclyl" contains a nitrogen atom, the point of attachment of the heterocyclyl group may be the nitrogen atom.

The terms "arylene", "heteroarylene", and "heterocyclylene" are the divalent forms of the "aryl", "heteroaryl", and "heterocyclyl" groups defined above. The terms, "arylenyl", "heteroarylenyl", and "heterocyclylenyl" are used when "arylene",

"heteroarylene," and "heterocyclylene", respectively, are substituted. For example, an alkylarylenyl group comprises an arylene moiety to which an alkyl group is attached.

When a group (or substituent or variable) is present more than once in any Formula described herein, each group (or substituent or variable) is independently selected, whether



5 explicitly stated or not. For example, for the formula $\neg(R_7)$ each R_7 group
is independently selected. In another example, when more than one Y group is present,
each Y group is independently selected. In a further example, when more than one
-N(R_8)-Q₁-R₄ group is present (e.g., more than one -Y-R₄ group is present, and both
contain a -N(R_8)-Q₁- group) each R_8 group is independently selected, each Q₁ group is
10 independently selected, and each R₄ group is independently selected.

The invention is inclusive of the compounds described herein (including intermediates) in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, polymorphs, prodrugs, and the like. In particular, if a compound is optically active, the invention specifically includes each of the compound's enantiomers as well as racemic and scalemic mixtures of the enantiomers. It should be understood that the term "compound" includes any or all of such forms, whether explicitly stated or not (although at times, "salts" are explicitly stated).

The term "prodrug" means a compound that can be transformed in vivo to yield an immune response modifying compound, including any of the salt, solvated, polymorphic, or isomeric forms described above. The prodrug, itself, may be an immune response modifying compound, including any of the salt, solvated, polymorphic, or isomeric forms described above. The transformation may occur by various mechanisms, such as through a chemical (e.g., solvolysis or hydrolysis, for example, in the blood) or enzymatic biotransformation. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A. C. S. Symposium Series, and in *Bioreversible Carriers in Drug Design*, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.

Compounds (including intermediates) of the present invention may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies, which are interconvertible via a low energy barrier. For example,

proton tautomers (prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. This is illustrated, for example, when compounds of the present invention have a hydrogen atom on an oxygen or nitrogen atom at the 2-position, allowing proton migration between the oxygen or nitrogen atom at the 2-position and the 3-position.

Preparation of the Compounds

Compounds of the invention may be synthesized by synthetic routes that include processes analogous to those well known in the chemical arts, particularly in light of the description contained herein. The starting materials are generally available from commercial sources such as Aldrich Chemicals (Milwaukee, Wisconsin, USA) or are readily prepared using methods well known to those skilled in the art (e.g., prepared by methods generally described in Louis F. Fieser and Mary Fieser, *Reagents for Organic Synthesis*, v. 1-19, Wiley, New York, (1967-1999 ed.); Alan R. Katritzky, Otto Meth-Cohn, Charles W. Rees, *Comprehensive Organic Functional Group Transformations*, v. 1-6, Pergamon Press, Oxford, England, (1995); Barry M. Trost and Ian Fleming, *Comprehensive Organic Synthesis*, v. 1-8, Pergamon Press, Oxford, England, (1991); or *Beilsteins Handbuch der organischen Chemie*, 4, Aufl. Ed. Springer-Verlag, Berlin, Germany, including supplements (also available via the Beilstein online database)).

For illustrative purposes, the reaction schemes depicted below provide potential routes for synthesizing the compounds of the present invention as well as key intermediates. For more detailed description of the individual reaction steps, see the EXAMPLES section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the compounds of the invention. Although specific starting materials and reagents are depicted in the reaction schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional methods well known to those skilled in the art.

In the preparation of compounds of the invention it may sometimes be necessary to protect a particular functionality while reacting other functional groups on an intermediate. The need for such protection will vary depending on the nature of the particular functional

group and the conditions of the reaction step. Suitable amino protecting groups include acetyl, trifluoroacetyl, *tert*-butoxycarbonyl (Boc), benzyloxycarbonyl, and 9-fluorenylmethoxycarbonyl (Fmoc). Suitable hydroxy protecting groups include acetyl and silyl groups such as the *tert*-butyl dimethylsilyl group. For a general description of


5 protecting groups and their use, see T. W. Greene and P. G. M. Wuts, *Protective Groups in Organic Synthesis*, 3rd edition, John Wiley & Sons, New York, USA, 1999.

Conventional methods and techniques of separation and purification can be used to isolate compounds of the invention, as well as various intermediates related thereto. Such techniques may include, for example, all types of chromatography (high performance

10 liquid chromatography (HPLC), column chromatography using common absorbents such as silica gel, and thin layer chromatography), recrystallization, and differential (i.e., liquid-liquid) extraction techniques.

Compounds of the invention can be prepared according to Reaction Scheme I, starting from a compound of Formula X in which R₁ and R₂ are as defined above and J₁

15 contains the necessary atoms to provide the following four 1*H*-imidazo[4,5-*c*]naphthyridin-4-amine isomers of Formulas XIII, XIV, XV, and XVI, wherein R and n are as defined above.




Many 1*H*-imidazo[4,5-*c*]naphthyridin-4-amine compounds of Formula X are known or

20 can be prepared by known methods. See, for example, U. S. Patent No. 6,194,425 (Gerster et al.), International Publication Nos. WO 2005/018551 (Kshirsagar et al.), WO 2005/018556 (Kshirsagar et al.), WO 2005/048945 (Kshirsagar et al.), WO 2005/048933 (Kshirsagar et al.), WO 2005/051324 (Krepiski et al.), WO 2005/123079 (Kshirsagar et al.), WO 2006/009832 (Dellaria et al.), WO 2006/029115 (Kshirsagar et al.), WO


25 2005/066169 (Bonk and Dellaria), WO 2006/028545 (Stoermer et al.), WO 2006/026760 (Stoermer et al.), WO 2006/028962 (Krepiski et al.), WO 2005/076783 (Radmer et al.), and WO 2005/094531 (Krepiski et al.), and International Application No. PCT/US2005/021570 (Moser et al.).

In step (1) of Reaction Scheme I, a 1*H*-imidazo[4,5-*c*]naphthyridin-4-amine of Formula X is reduced to provide a compound of Formula XI, or a salt thereof, wherein J₂ contains the necessary atoms to provide the following four 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridin-4-amine isomers of Formulas XVII, XVIII, XIX, and XX, wherein R and n are as defined above.



Several 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridin-4-amines of Formula XVII, XIX, and XX are known; see for example, U. S. Patent No. 6,194,425 (Gerster et al.), International Publication Nos. WO 2006/028545 (Stoermer et al.) and WO 2006/026760 (Stoermer et al.), and International Application No. PCT/US2005/021570 (Moser et al.). The reduction can be carried out under hydrogen pressure using a hydrogenation catalyst such as platinum oxide in a solvent such as trifluoroacetic acid. The reaction can be conveniently carried out on a Parr apparatus at room temperature.

In step (2) of Reaction Scheme I, the secondary amine in a 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridin-4-amine of Formula XI is functionalized with an R₃ group to form a compound of Formula XII, wherein J₃ contains the necessary atoms to provide the following compounds of the invention, Formulas I, II, III, and IV, wherein R, n, and R₃ are as defined above.



For some of the chemistry described below in the synthesis of compounds of Formula XII, protection and deprotection steps may be required. For example, in the synthesis of a substituted 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,5-naphthyridin-4-amine of Formula I and a substituted 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,8-naphthyridin-4-

amine of Formula IV, protection of the 4-amino group may be necessary before installation of the R_3 group. The 4-amino group can be protected as a cyclic imide such as an *N*-phthalimide or an *N*-succinimide by reaction of a 1*H*-imidazo[4,5-*c*]naphthyridine of Formula XIII or XVI with phthalic anhydride or succinic anhydride in a suitable solvent, such as chloroform or *N,N*-dimethylformamide (DMF), at elevated temperature. The protected 1*H*-imidazo[4,5-*c*]naphthyridine can then be reduced using the conditions described in step (1) of Reaction Scheme I to yield a 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridine where the 4-amino group is protected. Alternatively, the protection step can be carried out on a 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridine of Formula XVII or XX. The R_3 group can be installed using one of the methods described below in step (2) of Reaction Scheme I, and the cyclic imide protecting group can be removed with hydrazine to yield a compound of Formula I or IV.


A 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridin-4-amine of Formula XI or a salt thereof can be converted to an amide, sulfonamide, carbamate, sulfamide, or urea of Formula XII, i.e. R_3 is $-Q-R_4$, using conventional methods. For example, a compound of Formula XI or salt thereof can react with an acid chloride of Formula $R_4C(O)Cl$ to provide a compound of Formula XII wherein R_3 is $-C(O)-R_4$. In addition, a compound of the Formula XI can react with a sulfonyl chloride of Formula $R_4S(O)_2Cl$ or a sulfonic anhydride of Formula $(R_4S(O)_2)_2O$ to provide a compound of Formula XII wherein R_3 is $-S(O)_2-R_4$. A compound of the Formula XI can also react with a chloroformate of Formula $R_4CO(O)Cl$ to provide a compound of Formula XII in which R_3 is $-C(O)-O-R_4$. Numerous acid chlorides of Formula $R_4C(O)Cl$, sulfonyl chlorides of Formula $R_4S(O)_2Cl$, sulfonic anhydrides of Formula $(R_4S(O)_2)_2O$, and chloroformates of Formula $R_4CO(O)Cl$ are commercially available; others can be readily prepared using known synthetic methods. The reaction can be conveniently carried out by combining the acid chloride of Formula $R_4C(O)Cl$, chloroformate of Formula $R_4CO(O)Cl$, sulfonyl chloride of Formula $R_4S(O)_2Cl$, or sulfonic anhydride of Formula $(R_4S(O)_2)_2O$ with a compound of Formula XI and a base such as triethylamine in a suitable solvent such as chloroform, dichloromethane, or acetonitrile. The reaction can be carried out at room temperature or at a sub-ambient temperature such as 0 °C.

Ureas and thiourcas of Formula XII where R_3 is $-C(R_6)-N(R_8)-W-R_4$, wherein *W* is a bond, R_8 is H, and R_4 and R_6 are as defined above, can be prepared by reacting a


compound of Formula XI or a salt thereof with isocyanates of Formula $R_4N=C=O$ or isothiocyanates of Formula $R_4N=C=S$. Numerous isocyanates and isothiocyanates are commercially available; others can be readily prepared using known synthetic methods. The reaction can be conveniently carried out by adding the isocyanate or isothiocyanate to a cooled solution of a compound of Formula XI in a suitable solvent such as dichloromethane or chloroform. Optionally, a base such as triethylamine can be added. The reaction can be carried out at room temperature or at a sub-ambient temperature such as 0 °C.

Ureas and sulfamides of Formula XII where R_3 is $-C(R_6)-N(R_8)-W-R_4$ or $-S(O)_2-N(R_8)-R_4$, wherein R_6 is $=O$, W is a bond, and R_8 and R_4 are as defined above, can be synthesized by treating a compound of Formula XI with a carbamoyl chloride of Formula $R_4(R_8)N-C(O)Cl$ or a sulfamoyl chloride of Formula $R_4(R_8)N-S(O)_2Cl$ under the reaction conditions described above for reaction of compounds of Formula XI with acid chlorides. In addition, ureas and sulfamides of Formula XII where R_3 is $-C(O)-\text{heterocycle}$ or $-S(O)_2-\text{heterocycle}$ wherein heterocycle is, for example, pyrrolidine or morpholine, can be prepared from carbamoyl chlorides of Formula $Cl-C(O)-\text{heterocycle}$ or sulfamoyl chlorides of Formula $Cl-S(O)_2-\text{heterocycle}$. Some carbamoyl chlorides and sulfamoyl chlorides are commercially available; others can be prepared using known synthetic methods from commercially available amines of Formula $HN(R_8)R_4$ or appropriate cyclic amines.

An amide, urea, or sulfamide of Formula XII where R_3 is



wherein Q is $-C(O)-$ or $-S(O)_2-$, and D , Q_1 , and R_4 are as defined above can be prepared by treating a compound of Formula XI with an acid chloride, carbamoyl chloride, or sulfamoyl chloride of Formula



Some acid chlorides, carbamoyl chlorides, and sulfamoyl chlorides of this formula are commercially available, for example, 1-acetylpiperidine-4-carbonyl chloride and 4-methylpiperazine-1-carbonyl chloride; others can be prepared using known synthetic methods from piperidine-4-carboxylic acid or piperazine. When $-Q_1-R_4$ is a *tert*-

butoxycarbonyl (Boc) group in a compound of Formula XII, the protecting group can be removed under acidic conditions, and the resulting amine can be further elaborated using the methods described above to provide a sulfonamide, amide, carbamate, urea, thiourea, or sulfamide.

5 Compounds of Formula XII where R_3 is $-Z-Ar$, wherein Z is alkylene and Ar is as defined above, can be prepared by a reductive amination reaction between an aryl or arylalkylenyl aldehyde or ketone and a compound of Formula XI. Numerous aldehydes and ketones of this type are commercially available, especially substituted benzaldehydes. The reductive alkylation is conveniently carried out in two parts by (i) adding an aryl or
10 arylalkylenyl aldehyde or ketone to a solution of a compound of Formula XI or a salt thereof in a suitable solvent such as DMF in the presence of a base such as *N,N*-diisopropylethylamine. In part (ii) the reduction is carried out by adding a suitable reducing agent such as the borane-pyridine complex. Both part (i) and part (ii) can be carried out at room temperature.


15 Compounds of Formula XII where R_3 is $-Z-Ar$, wherein Z is alkylene, alkenylene, or alkynylene and Ar is as defined above, can also be prepared through an alkylation reaction with an arylalkylenyl, arylalkenylenyl, or arylalkynylenyl halide of Formula Halide- $Z-Ar$, where Halide is $-Cl$, $-Br$, or $-I$. The reaction is carried out by treating a compound of Formula XI with a compound of Formula Halide- $Z-Ar$ in a suitable solvent
20 such as ethanol, DMF, tetrahydrofuran (THF), or acetonitrile in the presence of a base such as triethylamine or potassium carbonate. The reaction can be carried out at room temperature or at elevated temperature. Numerous compounds of Formula Halide- $Z-Ar$ are commercially available, for example, substituted benzyl bromides and chlorides.

 Compounds of Formula XII where R_3 is $-Z-Ar$, wherein Z is a bond and Ar is as
25 defined above, can be prepared using an aromatic nucleophilic substitution reaction. A compound of Formula XI can react with an appropriately substituted aryl reagent, for example, 1-fluoro-2,4-dinitro-benzene, to yield a compound of Formula XII in which Ar is a 2,4-dinitrobenzene group. Alternatively, a compound of Formula XI can undergo a palladium-mediated coupling reaction with an aryl halide to yield a compound of Formula
30 XII.


 Compounds of Formula XII where R_3 is $-alkylene-CH(CH_2-OH)-OH$,

-alkylene-CH(CH₂CH₂-OH)-OH, and -(alkylene)₀₋₁-CH(CH₂OH)₂ can be prepared by a reductive amination reaction between a dihydroxy aldehyde or ketone and a compound of Formula XI. For example, a ketone of Formula HO-CH₂-C(O)-CH₂-OH can be reacted with a compound of Formula XI under the conditions described above for a reductive amination reaction to provide a compound of Formula XII in which R₃ is -CH(CH₂OH)₂. A dihydroxy aldehyde or ketone wherein the hydroxyl groups are protected with an appropriate protecting group or groups can also be used in the reductive amination reaction; subsequent deprotection provides a compound of Formula XII. Many protected dihydroxy aldehydes and ketones are known in the literature and can be readily synthesized; see, for example, Howson, W. *et al Eur. J. Med. Chem. Chim. Ther.* 25, pp. 595-602 (1990); Hon, Y.-S. *et al. Tetrahedron*, 57, 6181-6188, (2001); and Rao, A. V. R. *et al. Carbohydr. Res.* 148, 51-56, (1986).


A compound of Formula XII where R₃ is



; wherein Z is a bond, alkylene, or -CH₂-alkylene, E is -O-, -S(O)₀₋₂-, or -N(Q₁-R₄)-, and R₁₀ is as defined above; can be prepared by alkylation of a compound of




Formula XI with a reagent of Formula , or through a reductive amination between a compound of Formula XI and a compound of Formula




using the conditions described above. Some useful reagents are commercially available, for example, *tert*-butyl 4-(bromomethyl)piperidine-1-carboxylate, 4-(bromomethyl)tetrahydro-2*H*-pyran, and 4-(bromomethyl)piperidine; other reagents can be prepared using known synthetic methods. If E is -N(Q₁-R₄)-, wherein Q₁-R₄ is a protecting group, the protecting group can subsequently be removed, and the resulting amine can be converted into an amide, urea, thiourea, carbamate, sulfonamide, or sulfamide using one of the methods described above.

A Michael addition reaction can be used to prepare a compound of Formula XII in




which R_3 is $-X-Y-R_4$, $-X-R_5$, or wherein X is alkylene; Y and R_4 are as defined above, R_5 is $-\text{CN}$, Z is a bond, E is $-\text{C}(\text{O})-$, and R_{10} is C_{4-6} alkylene. For example, a compound of Formula XI can be treated with an α,β -unsaturated sulfone, ketone, ester, amide, or nitrile of Formula $\text{H}_2\text{C}=\text{C}(\text{H})-Y-R_4$ or $\text{H}_2\text{C}=\text{C}(\text{H})-R_5$ to provide a compound of Formula XII where R_3 is $-\text{CH}_2\text{CH}_2-Y-R_4$ or $-\text{CH}_2\text{CH}_2-R_5$, wherein Y is $-\text{S}(\text{O})_2-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})-\text{O}-$, $-\text{C}(\text{O})-\text{N}(\text{H})-$, and R_5 is $-\text{CN}$. Many α,β -unsaturated sulfones, ketones, esters, amides, and nitriles are commercially available, others can be prepared readily through known methods. The reaction can also be carried out with cyclic α,β -unsaturated ketones such as 2-cyclohexene-1-one to provide a compound of Formula XII wherein R_3 is




The reaction can be conveniently carried out by adding an α,β -unsaturated sulfone, ketone, ester, amide, or nitrile to a solution of a compound of Formula XI in a suitable solvent such as THF or acetonitrile optionally in the presence of a base such as triethylamine. The reaction can be carried out at room temperature or at an elevated temperature, for example, the reflux temperature of the solvent. An alkyne of Formula $\text{HC}\equiv\text{C}-Y-R_4$ or $\text{HC}\equiv\text{C}-R_5$ can be used in place of an alkene of Formula $\text{H}_2\text{C}=\text{C}(\text{H})-Y-R_4$ or $\text{H}_2\text{C}=\text{C}(\text{H})-R_5$ in the Michael reaction to yield compound of Formula XII in which R_3 is $-X-Y-R_4$ or $-X-R_5$ wherein X is alkenylene. Additional compounds of the invention of Formula XII where R_3 is $-X-Y-R_4$ or $-X-R_5$ can be prepared through alkylation of a compound of Formula XI with a reagent of Formula Halide- $X-Y-R_4$ or Halide- $X-R_5$; or by a reductive amination reaction between an aldehyde of Formula $\text{H}(\text{O})\text{C}-X-Y-R_4$ or $\text{H}(\text{O})\text{C}-X-R_5$ with a compound of Formula XI using the conditions described above for an alkylation or a reductive amination.

A compound of Formula XII in which R_3 is $-X-Y-R_4$ or $-X-R_5$ obtained from a Michael reaction or by other means, can be elaborated to provide additional compounds of the invention. For example, compounds of Formula XII in which R_3 is $-X-\text{CN}$ or $-X-\text{CO}_2\text{R}_4$ can be treated with a reducing agent such as lithium aluminum hydride to provide a compound of Formula XII in which R_3 is $-X-\text{CH}_2-\text{NH}_2$ or $-X-\text{CH}_2-\text{OH}$,

respectively. The amino group in a compound of Formula XII where R_3 is $-X-CH_2-NH_2$ can be converted to an amide, urea, thiourea, carbamate, sulfonamide, or sulfamide of Formula XII in which R_3 is $-X-CH_2-N(R_8)-Q_1-R_4$ using the methods described above. The amino group can also be treated with an acid chloride of Formula $Cl-R_7C(O)Cl$ or a sulfonyl chloride of Formula $Cl-R_7S(O)_2Cl$ using the reaction conditions described above. The isolable intermediate chloroalkanesulfonamide or chloroalkanamide can then be treated with a base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) or sodium hydride at room temperature in a suitable solvent such as DMF to effect a cyclization and provide a compound of Formula XII in which R_3 is $-X-CH_2-R_5$, wherein R_5 is




A hydroxyalkyl-substituted compound of Formula XII, in which R_3 is $-X-OH$ or $-X-CH_2-OH$, can be treated with *N*-hydroxyphthalimide under Mitsunobu reaction conditions to provide an *N*-phthalimide-protected hydroxylamine. The reaction can be conveniently carried out by adding triphenylphosphine and *N*-hydroxyphthalimide to a solution of the hydroxyalkyl-substituted compound in a suitable solvent such as THF or DMF and then slowly adding diisopropyl azodicarboxylate. The reaction can be carried out at room temperature or at an elevated temperature, such as 60 °C. The phthalimide group can then be removed from the resulting *N*-phthalimide-protected hydroxylamine by treatment with hydrazine at room temperature in a suitable solvent such as ethanol. The resulting hydroxylamine can then be treated with one of numerous commercially available aldehydes or ketones in a suitable solvent such as methanol to provide an oxime in a compound of Formula XII where R_3 is $-X-Y-R_4$ or $-X-R_5$, wherein Y is $-O-N=C(R_4)-$, R_5 is



hydroxylamine prepared after the hydrazine deprotection may be treated with one of numerous acid chlorides, sulfonyl chlorides, isocyanates, carbamoyl chlorides, or sulfamoyl chlorides as described above to provide a compound of the invention wherein R_3 is $-X-Y-R_4$ where Y is $-O-NH-Q_1-$, and Q_1 and R_4 are as defined above.


The alcohol in a compound of Formula XII wherein R_3 is $-X-OH$ or $-X-CH_2-OH$, can be converted into a chloride group that can be displaced by a nucleophile, such as a cyclic amine of Formula



5 , wherein a, b, and A are as defined above. Several cyclic amines of this formula are commercially available; others can be prepared by conventional methods. The chlorination reaction can be conveniently carried out by combining a hydroxyl-substituted compound of Formula XII with thionyl chloride in a suitable solvent such as dichloromethane at room temperature. The resulting chloro-substituted compound is then combined with a cyclic amine in the presence of a base such as potassium carbonate and in
10 a suitable solvent such as DMF. Catalytic sodium iodide can optionally be added. The reaction can be carried out at an elevated temperature such as 50 °C or 90 °C-100 °C. These reaction conditions also can be used employing a variety of phenols to provide compounds of Formula XII where R_3 is $-X-Y-R_4$ where Y is $-O-$ and R_4 is an unsubstituted or substituted phenyl group.


15 In another example, a ketone of Formula XII, which is a compound of the invention wherein R_3 is $-X-Y-R_4$ where Y is $-C(O)-$, X is alkylene, and R_4 is as defined above, which may be obtained through a Michael reaction, can be converted to an oxime, wherein Y is $-C(=N-OR_8)-$, and R_8 is as defined above. The reaction can be carried out by combining an aqueous solution of a hydroxylamine salt of Formula $NH_2OR_8 \cdot HCl$ and a
20 solution of the ketone in a suitable solvent such as methanol or ethanol and then adding a base such as sodium hydroxide and heating at an elevated temperature. The oxime so prepared may be reduced with sodium cyanoborohydride in a mixture of ethanol or methanol in acetic acid to provide a hydroxylamine, which may be treated with one of numerous acid chlorides, sulfonyl chlorides, isocyanates, carbamoyl chlorides, or
25 sulfamoyl chlorides as described above to provide a compound of the invention wherein R_3 is $-X-Y-R_4$ wherein Y is $-CH(-N-(OR_8)-Q_1-R_4)-$, and Q_1 and R_8 are as defined above.

Reaction Scheme I




1H-Imidazo[4,5-c]naphthyridin-4-amine compounds of Formula XII can also be prepared according to Reaction Scheme II wherein R₁, R₂, J₁, and J₃ are as defined above, Hal is -Br or -I, M is -B(O-alkyl)₂, -B(OH)₂, -Sn(alkyl)₃, or -Zn-Halide, D₁ is hydrogen, -C(O)C(CH₃)₃ (*tert*-butylcarbonyl), or Boc, and J₄ and J₅ are defined below. In step (1) of Reaction Scheme II, aminomalonitrile (Formula XXI), which is available commercially as the *p*-toluenesulfonic acid salt, is reacted with an orthoester to generate an imidate intermediate, which is treated with a primary amine. The orthoester and amine are selected such that they will provide the desired R₂ and R₁ substituents in a compound of Formula XXII. The reaction can be conveniently carried out by heating a solution of aminomalonitrile *p*-toluenesulfonate and the orthoester in a suitable solvent such as THF in the presence of a base such as triethylamine. The solution is allowed to cool to ambient temperature and the primary amine is added. Numerous primary amines suitable for this reaction are commercially available; others can be prepared by known methods. See, for example, the methods in U.S. Patent Nos. 6,451,810 (Coleman et al.), 6,660,747 (Crooks et al.), 6,683,088 (Crooks et al.), and 6,656,938 (Crooks et al.); U.S. Patent Application Publication No. 2004/0147543 (Hays et al.); International Patent Application Publication Nos. WO 2005/066169 (Bonk and Dellaria), WO 2006/028545 (Stoermer et al.), WO 2005/051317 (Krepiski et al.), WO 2005/076783 (Radmer et al.), and WO 2005/094531 (Krepiski et al.); and International Application No. PCT/US2005/021570 (Moser et al.).

Certain amines of Formula R₁-NH₂ provide a compound of Formula XXII that contain a functional group or protected functional group that can be transformed in a subsequent step in Reaction Scheme II to provide compounds of Formula XII with a variety of different R₁ groups. For example, amines of formula R₁NH₂ may contain a protected functional group, such as a Boc-protected amino group. For example, protected



are commercially available or can be prepared by known methods; see, for example, U.S. Patent Nos. 6,660,747 (Crooks et al.), 6,683,088 (Crooks et al.), and 6,656,938 (Crooks et al.) and Carceller, E. et al., *J. Med. Chem.*, 39, pp.487-493 (1996). The protecting group may be removed, for example, after step (4) of Reaction Scheme II, and the resultant amino group can be functionalized using one of the methods described in step (2) of Reaction Scheme I to provide a compound of the invention in which R_1 is $\text{-X-N(R}_8\text{)-Q}_1\text{-R}_4$,



defined above.

Amines of formula R_1NH_2 can also contain other protected functional groups, such as ketal-protected ketones. For example, 2,2-dimethyl-3-(2-methyl-1,3-dioxolan-2-yl)propylamine, prepared in Example 22 of International Patent Application Publication Nos. WO2005/051317 (Krepiski et al.), can be used, and the ketal protecting group can later be removed by conventional methods to provide a compound of the invention in which R_1 is 2,2-dimethyl-4-oxopentyl.

Amino alcohols of formula $\text{H}_2\text{N-X-OH}$ can be used, and the hydroxy functional group can be converted in subsequent steps, for example, after step (4), to a compound of the invention having an $\text{-X-S(O)}_{0-2}\text{-R}_4$, $\text{-X-S(O)}_2\text{-N(R}_8\text{)-R}_4$, $\text{-X-O-N(R}_8\text{)-Q}_1\text{-R}_4$, $\text{-X-O-N=C(R}_4\text{)-R}_4$, $\text{-X-CH(-N(-O-R}_8\text{)-Q}_1\text{-R}_4\text{)-R}_4$ group at the R_1 position using methods described in U. S. Patent No. 6,664,264 (Dellaria et al.) and International Patent Application Publication Nos. WO2005/066169 (Bonk and Dellaria), WO2005/018551 (Kshirsagar et al.), WO2005/018556 (Kshirsagar et al.), and WO2005/051324 (Krepiski et al.), respectively.


The amine of formula R_1NH_2 may be *tert*-butyl carbazate, and the resulting R_1 group can be manipulated in subsequent steps, for example, after step (4), using the methods of U.S. Patent Application Publication No. 2006/026760 to provide compounds of the invention wherein R_1 is $\text{-N(R}_1'\text{)-Q}_1\text{-R}_4$, $\text{-N(R}_1'\text{)-X}_1\text{-Y}_1\text{-R}_4$, or $\text{-N(R}_1'\text{)-X}_1\text{-R}_{5a}$.

Other transformations at the R₁ position can be made. See, for example, U.S. Patent Nos. 5,389,640 (Gerster et al.), 6,331,539 (Crooks et al.), 6,451,810 (Coleman et al.), 6,541,485 (Crooks et al.), 6,660,747 (Crooks et al.), 6,670,372 (Charles et al.), 6,683,088 (Crooks et al.), 6,656,938 (Crooks et al.), 6,664,264 (Dellaria et al.), 6,677,349 (Griesgraber), and 6,664,260 (Charles et al.).

Functional group transformations can also be made at the R₂ position in a number of compounds shown in Reaction Scheme II if the orthoester used in step (1) contains a protected hydroxy group, for example. See the methods in, for example, U.S. Patent No. 5,389,640 (Gerster et al.) and International Publication Nos. WO 2005/018551 (Kshirsagar et al.), WO 2005/048945 (Kshirsagar et al.) and WO 2005/048933 (Kshirsagar et al.).

In step (2) of Reaction Scheme II, a compound of Formula XXII is added to a solution of bromoform or diiodomethane and an alkyl nitrite such as isoamyl nitrite or *tert*-butyl nitrite to yield a compound of Formula XXIII where Hal is Br or I, respectively. The reaction can be carried out at an elevated temperature such as 90 °C, and a co-solvent such as chloroform can be employed.


In step (3) of Reaction Scheme II, an iodo- or bromo-substituted compound of Formula XXIII undergoes a transition-metal catalyzed cross coupling reaction with a reagent of Formula XXIV, in which J₄ contains the necessary atoms to provide a compound of Formula XXIV as the following four pyridine isomers of Formula XXVI, XXVII, XXVIII, and XXIX, wherein R and n are as defined above:



Reagents of Formula XXIV are known to undergo coupling reactions, such as Suzuki couplings, Stille couplings, and Negishi couplings, and are either commercially available or can be prepared using known synthetic methods. A compound of Formula XXVI, 3-amino-2-tri-*n*-butylstannylpyridine, can be prepared by a halogen-lithium exchange of a 2-bromopyridine that has a protected amino group in the 3-position

followed by reaction with tributyltin chloride and deprotection of the amino group. A reagent of Formula XXVII is commercially available (2,2-dimethyl-*N*-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-4-yl]propanamide, CB Research and Development, Inc. in New Castle, DE). Compounds of Formula XXVII, XXVIII, and XXIX can be prepared starting from *tert*-butylcarbonyl or Boc-protected 4-, 3-, and 2-aminopyridines, which undergo directed ortho metalation in the presence of butyllithium reagents. The resulting organolithium intermediate can react with electrophiles such as B(O-alkyl)₃ and ClSn(alkyl)₃ to provide compounds of Formula XXIV, where M is -B(O-alkyl)₂ or -B(OH)₂ and -Sn(alkyl)₃, respectively. The Boc protecting group can be removed with acid to provide a compound of Formula XXIV where D₁ is hydrogen.

In step (3), a Suzuki coupling reaction can be conveniently carried out by heating a mixture of the compound of Formula XXIII, palladium (II) acetate, triphenylphosphine, and a boron reagent of Formula XXIV, where M is -B(OH)₂ or -B(O-alkyl)₂, in the presence of a base such as sodium carbonate. The reaction can be carried out in a suitable solvent or solvent mixture such as *n*-propanol:water and can be heated at an elevated temperature such as 100 °C. The product of the Suzuki coupling is a compound of Formula XXV where J₅ contains the necessary atoms to provide the following four isomers of Formula XXX, XXXI, XXXII, and XXXIII, wherein R and n are as defined above.




In step (4) of Reaction Scheme II, a compound of Formula XXV cyclizes to form a 1*H*-imidazo[4,5-*c*]naphthyridin-4-amine of Formula X. When the Suzuki reaction in step (3) is carried out with a compound of Formula XXIV wherein D₁ is hydrogen or Boc, the cyclization can be carried out under acidic conditions. The intramolecular cyclization can be conveniently carried out by treating a compound of Formula XXV with a solution of hydrochloric acid in ethanol. The reaction is then heated at reflux to provide a 1*H*-

imidazo[4,5-*c*]naphthyridin-4-amine of Formula X. Alternatively, a compound of Formula XXV wherein D₁ is hydrogen may undergo cyclization to the compound of Formula X under the Suzuki coupling reaction conditions in step (3).

When the Suzuki reaction in step (3) is carried out with a compound of Formula XXIV wherein D₁ is *tert*-butylcarbonyl, the cyclization in step (4) can be carried out under basic conditions. The reaction can be conveniently carried out by heating a compound of Formula XXV with potassium *tert*-butoxide in a suitable solvent such as ethanol at an elevated temperature such as the reflux temperature of the solvent.

In steps (5) and (6) of Reaction Scheme II, a 1*H*-imidazo[4,5-*c*]naphthyridin-4-amine of Formula X is transformed into a compound of Formula XII using the methods discussed in steps (1) and (2), respectively, of Reaction Scheme I.

Reaction Scheme II



For some embodiments, compounds of the invention can be prepared according to Reaction Scheme III wherein R, R₁, and n are as defined above; Hal, M, and D₁ are defined as in Scheme II, and P is a protecting group, for example, an alkyl or benzyl group. Compounds of Formula XXIIa can be prepared by reacting aminomalonitrile or a salt thereof with triphosgene and a primary amine of Formula R₁-NH₂. The reaction can be conveniently carried out in a suitable solvent such as THF in the presence of

triethylamine or *N,N*-diisopropylethylamine. See, for example, the method described by Hirota, K. *et al.*, *Heterocycles*, 55, pp. 2279-2282 (2001).

5 In step (1) of Reaction Scheme III, a 2-hydroxy imidazole of Formula XXIIa is protected as an alkyl or benzyl ether to provide an imidazole of Formula XXIIb. The reaction can be carried out by treating a compound of Formula XXIIa with an alkyl or benzyl halide in the presence of a base such as potassium carbonate in a suitable solvent such as acetone, methanol, or ethanol. The reaction can be carried out at room temperature or at an elevated temperature such as the reflux temperature of the solvent.


10 In steps (2) through (4) of Reaction Scheme III, a compound of Formula XXIIb is converted into a 1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine of Formula XIVa using the methods described in steps (2) through (4) of Reaction Scheme II.

15 In step (5) of Reaction Scheme III, a 1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine of Formula XIVa is converted to a 4-amino-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-2-ol of Formula XIVb using conventional dealkylation methods. For example, a dealkylation reaction can be carried out by treating a compound of Formula XIVa wherein P is a C₁₋₄ alkyl group with boron tribromide in a suitable solvent such as dichloromethane at room temperature or a sub-ambient temperature such as -78 °C. A compound of Formula XIVa wherein P is benzyl can be deprotected by heterogeneous hydrogenation or by treatment with trifluoroacetic acid using conditions known to one of skill in the art.

20 In steps (6) and (7), a compound of Formula XIVb can be converted into a compound of the invention of Formula IIb using the methods described in steps (1) and (2) of Reaction Scheme I. Other naphthyridine isomers can be formed if pyridine isomers of Formula XXVI, XXVIII, or XXIX are used instead of the pyridine of Formula XXVII in step (3) of Reaction Scheme III.

25


Reaction Scheme III



For certain embodiments, compounds of the invention can be prepared according to Reaction Scheme IV, wherein R_1 , R_2 , G , and J_3 are as defined above, and J_6 contains the necessary atoms to provide a compound of Formula XXV as the compounds of the invention of Formula V, VI, VII, and VIII. Compounds of Formula XII can be prepared according to the methods described above in Reaction Schemes I, II, or III. The 4-amino group of a compound of a 6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]naphthyridin-4-amine of Formula XII can be converted using conventional methods to a functional group such as an amide, carbamate, urea, amidine, or another hydrolyzable group by the replacement of a hydrogen atom in an amino group with a group such as $-C(O)-R'$, α -aminoacyl, α -aminoacyl- α -aminoacyl, $-C(O)-O-R'$, $-C(O)-N(R'')-R'$, $-C(=NY')-R'$, $-CH(OH)-C(O)-OY'$, $-CH(OC_{1-4} \text{ alkyl})Y_0$, $-CH_2Y_2$, or $-CH(CH_3)Y_2$; wherein R' and R'' are each independently C_{1-10} alkyl, C_{3-7} cycloalkyl, phenyl, benzyl, or 2-phenylethyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, nitro, cyano, carboxy, C_{1-6} alkyl, C_{1-4} alkoxy, aryl, heteroaryl, aryl- C_{1-4} alkylenyl, heteroaryl- C_{1-4} alkylenyl, halo- C_{1-4} alkylenyl, halo- C_{1-4} alkoxy, $-O-C(O)-CH_3$, $-C(O)-O-CH_3$, $-C(O)-NH_2$,

-O-CH₂-C(O)-NH₂, -NH₂, and -S(O)₂-NH₂; with the proviso that R" may also be hydrogen; each α-aminoacyl group is independently selected from racemic, D, or L-amino acids; Y' is hydrogen, C₁₋₆ alkyl, or benzyl; Y₀ is C₁₋₆ alkyl, carboxyC₁₋₆ alkylenyl, aminoC₁₋₄ alkylenyl, mono-*N*-C₁₋₆ alkylaminoC₁₋₄ alkylenyl, or di-*N,N*-C₁₋₆ alkylaminoC₁₋₄ alkylenyl; and Y₂ is mono-*N*-C₁₋₆ alkylamino, di-*N,N*-C₁₋₆ alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, or 4-C₁₋₄ alkylpiperazin-1-yl. Particularly useful compounds of Formula XXXIV are amides derived from carboxylic acids containing one to ten carbon atoms, amides derived from amino acids, and carbamates containing one to ten carbon atoms. The reaction can be carried out, for example, by combining a compound of Formula XII with a chloroformate or acid chloride, such as ethyl chloroformate or acetyl chloride, in the presence of a base such as triethylamine in a suitable solvent such as dichloromethane at room temperature.

Reaction Scheme IV



Other prodrugs can be prepared in a variety of ways. For example, a compound wherein R₁ or R₂ is hydroxyalkyl can be converted into a prodrug wherein R₁ or R₂ is, for example, -alkylenyl-O-C(R₆)-R₄, -alkylenyl-O-C(R₆)-O-R₄, or -alkylenyl-O-C(R₆)-N(R₈)-R₄, wherein R₄, R₆, and R₈ are as defined above, using methods known to one skilled in the art. In addition, a compound wherein R is hydroxy or a compound of Formula IIb or its positional isomers may also be converted to an ester, an ether, a carbonate, or a carbamate. For any of these compounds containing an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as C₁₋₆ alkanoyloxymethyl, 1-(C₁₋₆ alkanoyloxy)ethyl, 1-methyl-1-(C₁₋₆ alkanoyloxy)ethyl, C₁₋₆ alkoxycarbonyloxymethyl, N-(C₁₋₆ alkoxycarbonyl)aminomethyl, succinoyl, C₁₋₆ alkanoyl, α-aminoC₁₋₄ alkanoyl, arylacyl, -P(O)(OH)₂, -P(O)(O-C₁₋₆ alkyl)₂, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylcarbamoyl, and

α -aminoacyl or α -aminoacyl- α -aminoacyl, where each α -aminoacyl group is independently selected from the naturally occurring racemic, D-, and L-amino acids. For compounds containing an alcohol functional group, particularly useful prodrugs are esters made from carboxylic acids containing one to six carbon atoms, unsubstituted or substituted benzoic acid esters, or esters made from naturally occurring L-amino acids. These esters can be prepared by heating a compound of Formula IIb, for example, with a carboxylic acid optionally in the presence of a base. The esterification reaction can be carried out in a suitable solvent such as methanol or ethanol. Alternatively, for compounds wherein R₁ or R₂ is hydroxyalkyl, the reaction can be carried out by treating the compound with a carboxylic acid or amino acid under Mitsunobu reaction conditions in the presence of triphenylphosphine and diisopropyl azodicarboxylate in a suitable solvent such as THF. The reaction can be run at a sub-ambient temperature such as 0 °C.

Compounds of the invention can also be prepared using variations of the synthetic route shown in Reaction Schemes I through IV that would be apparent to one of skill in the art, including variations described in the EXAMPLES below.

Pharmaceutical Compositions and Biological Activity

Pharmaceutical compositions of the invention contain a therapeutically effective amount of a compound or salt described above in combination with a pharmaceutically acceptable carrier.

The terms "a therapeutically effective amount" and "effective amount" mean an amount of the compound or salt sufficient to induce a therapeutic or prophylactic effect, such as cytokine induction, immunomodulation, antitumor activity, and/or antiviral activity. The exact amount of compound or salt used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound or salt, the nature of the carrier, and the intended dosing regimen.

In some embodiments, the compositions of the invention will contain sufficient active ingredient or prodrug to provide a dose of about 100 nanograms per kilogram (ng/kg) to about 50 milligrams per kilogram (mg/kg), preferably about 10 micrograms per kilogram (μ g/kg) to about 5 mg/kg, of the compound or salt to the subject.

In other embodiments, the compositions of the invention will contain sufficient active ingredient or prodrug to provide a dose of, for example, from about 0.01 mg/m² to about 5.0 mg/m², computed according to the Dubois method, in which the body surface area of a subject (m²) is computed using the subject's body weight: $m^2 = (wt\ kg^{0.425} \times$
5 height $cm^{0.725}) \times 0.007184$, although in some embodiments the methods may be performed by administering a compound or salt or composition in a dose outside this range. In some of these embodiments, the method includes administering sufficient compound to provide a dose of from about 0.1 mg/m² to about 2.0 mg/m² to the subject, for example, a dose of from about 0.4 mg/m² to about 1.2 mg/m².

10 A variety of dosage forms may be used, such as tablets, lozenges, capsules, parenteral formulations, syrups, creams, ointments, aerosol formulations, transdermal patches, transmucosal patches and the like. These dosage forms can be prepared with conventional pharmaceutically acceptable carriers and additives using conventional methods, which generally include the step of bringing the active ingredient into
15 association with the carrier.

The compounds or salts of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds or salts described herein may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, antibodies,
20 proteins, peptides, oligonucleotides, etc.

Compounds or salts of the invention have been shown to induce the production of certain cytokines in experiments performed according to the tests set forth below. These results indicate that the compounds or salts are useful for modulating the immune response in a number of different ways, rendering them useful in the treatment of a variety of
25 disorders.

Cytokines whose production may be induced by the administration of compounds or salts of the invention generally include interferon- α (IFN- α) and tumor necrosis factor- α (TNF- α) as well as certain interleukins (IL). Cytokines whose biosynthesis may be induced by compounds or salts of the invention include IFN- α , TNF- α , IL-1, IL-6, IL-10
30 and IL-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds or salts useful in the treatment of viral diseases and neoplastic diseases. Accordingly, the

invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of the invention to the animal. The animal to which the compound or salt is administered for induction of cytokine biosynthesis may have a disease as described *infra*, for example a viral disease or a neoplastic disease, and administration of the compound or salt may provide therapeutic treatment. Alternatively, the compound or salt may be administered to the animal prior to the animal acquiring the disease so that administration of the compound or salt may provide a prophylactic treatment.

In addition to the ability to induce the production of cytokines, compounds or salts described herein can affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction. The compounds or salts may also activate macrophages, which in turn stimulate secretion of nitric oxide and the production of additional cytokines. Further, the compounds or salts may cause proliferation and differentiation of B-lymphocytes.

Compounds or salts described herein can also have an effect on the acquired immune response. For example, the production of the T helper type 1 (T_H1) cytokine IFN- γ may be induced indirectly and the production of the T helper type 2 (T_H2) cytokines IL-4, IL-5 and IL-13 may be inhibited upon administration of the compounds or salts.

Whether for prophylaxis or therapeutic treatment of a disease, and whether for effecting innate or acquired immunity, the compound or salt or composition may be administered alone or in combination with one or more active components as in, for example, a vaccine adjuvant. When administered with other components, the compound or salt or composition and other component or components may be administered separately; together but independently such as in a solution; or together and associated with one another such as (a) covalently linked or (b) non-covalently associated, e.g., in a colloidal suspension.

Conditions for which compounds or salts or compositions identified herein may be used as treatments include, but are not limited to:

(a) viral diseases such as, for example, diseases resulting from infection by an adenovirus, a herpesvirus (e.g., HSV-I, HSV-II, CMV, or VZV), a poxvirus (e.g., an orthopoxvirus such as variola or vaccinia, or molluscum contagiosum), a picornavirus (e.g., rhinovirus or enterovirus), an orthomyxovirus (e.g., influenzavirus), a paramyxovirus

(e.g., parainfluenzavirus, mumps virus, measles virus, and respiratory syncytial virus (RSV)), a coronavirus (e.g., SARS), a papovavirus (e.g., papillomaviruses, such as those that cause genital warts, common warts, or plantar warts), a hepadnavirus (e.g., hepatitis B virus), a flavivirus (e.g., hepatitis C virus or Dengue virus), or a retrovirus (e.g., a lentivirus such as HIV);

(b) bacterial diseases such as, for example, diseases resulting from infection by bacteria of, for example, the genus *Escherichia*, *Enterobacter*, *Salmonella*, *Staphylococcus*, *Shigella*, *Listeria*, *Aerobacter*, *Helicobacter*, *Klebsiella*, *Proteus*, *Pseudomonas*, *Streptococcus*, *Chlamydia*, *Mycoplasma*, *Pneumococcus*, *Neisseria*, *Clostridium*, *Bacillus*, *Corynebacterium*, *Mycobacterium*, *Campylobacter*, *Vibrio*, *Serratia*, *Providencia*, *Chromobacterium*, *Brucella*, *Yersinia*, *Haemophilus*, or *Bordetella*;

(c) other infectious diseases, such as chlamydia, fungal diseases including but not limited to candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, or parasitic diseases including but not limited to malaria, pneumocystis carinii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and trypanosome infection;

(d) neoplastic diseases, such as intraepithelial neoplasias, cervical dysplasia, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, renal cell carcinoma, Kaposi's sarcoma, melanoma, leukemias including but not limited to acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma, and hairy cell leukemia, and other cancers;

(e) T_H2-mediated, atopic diseases, such as atopic dermatitis or eczema, eosinophilia, asthma, allergy, allergic rhinitis, and Ommen's syndrome;

(f) certain autoimmune diseases such as systemic lupus erythematosus, essential thrombocythaemia, multiple sclerosis, discoid lupus, alopecia areata; and

(g) diseases associated with wound repair such as, for example, inhibition of keloid formation and other types of scarring (e.g., enhancing wound healing, including chronic wounds).

Additionally, a compound or salt identified herein may be useful as a vaccine adjuvant for use in conjunction with any material that raises either humoral and/or cell mediated immune response, such as, for example, live viral, bacterial, or parasitic immunogens; inactivated viral, tumor-derived, protozoal, organism-derived, fungal, or

bacterial immunogens; toxoids; toxins; self-antigens; polysaccharides; proteins; glycoproteins; peptides; cellular vaccines; DNA vaccines; autologous vaccines; recombinant proteins; and the like, for use in connection with, for example, BCG, cholera, plague, typhoid, hepatitis A, hepatitis B, hepatitis C, influenza A, influenza B, parainfluenza, polio, rabies, measles, mumps, rubella, yellow fever, tetanus, diphtheria, hemophilus influenza b, tuberculosis, meningococcal and pneumococcal vaccines, adenovirus, HIV, chicken pox, cytomegalovirus, dengue, feline leukemia, fowl plague, HSV-1 and HSV-2, hog cholera, Japanese encephalitis, respiratory syncytial virus, rotavirus, papilloma virus, yellow fever, and Alzheimer's Disease.

10 Compounds or salts identified herein may be particularly helpful in individuals having compromised immune function. For example, compounds or salts may be used for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HIV patients.

15 Thus, one or more of the above diseases or types of diseases, for example, a viral disease or a neoplastic disease may be treated in an animal in need thereof (having the disease) by administering a therapeutically effective amount of a compound or salt of the invention to the animal.

20 An animal may also be vaccinated by administering an effective amount of a compound or salt described herein, as a vaccine adjuvant. In one embodiment, there is provided a method of vaccinating an animal comprising administering an effective amount of a compound or salt described herein to the animal as a vaccine adjuvant.

25 An amount of a compound or salt effective to induce cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN- α , TNF- α , IL-1, IL-6, IL-10 and IL-12 that is increased (induced) over a background level of such cytokines. The precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 μ g/kg to about 5 mg/kg. In other embodiments, the amount is expected to be a dose of, for example, from about 0.01 mg/m² to about 5.0 mg/m²,
30 (computed according to the Dubois method as described above) although in some embodiments the induction or inhibition of cytokine biosynthesis may be performed by administering a compound or salt in a dose outside this range. In some of these

embodiments, the method includes administering sufficient compound or salt or composition to provide a dose of from about 0.1 mg/m² to about 2.0 mg/ m² to the subject, for example, a dose of from about 0.4 mg/m² to about 1.2 mg/m².

5 The invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or salt of the invention to the animal. An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals. The precise
10 amount that is effective for such treatment will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 µg/kg to about 5 mg/kg. An amount of a compound or salt effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci. Again, the precise amount will vary according to factors known in the art but is
15 expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 µg/kg to about 5 mg/kg. In other embodiments, the amount is expected to be a dose of, for example, from about 0.01 mg/m² to about 5.0 mg/m², (computed according to the Dubois method as described above) although in some embodiments either of these methods may be performed by administering a compound or salt in a dose outside this range. In some of
20 these embodiments, the method includes administering sufficient compound or salt to provide a dose of from about 0.1 mg/m² to about 2.0 mg/ m² to the subject, for example, a dose of from about 0.4 mg/m² to about 1.2 mg/m².

In addition to the formulations and uses described specifically herein, other formulations, uses, and administration devices suitable for compounds of the present
25 invention are described in, for example, International Publication Nos. WO 03/077944 and WO 02/036592, U.S. Patent No. 6,245,776, and U.S. Publication Nos. 2003/0139364, 2003/185835, 2004/0258698, 2004/0265351, 2004/076633, and 2005/0009858.

30 Objects and advantages of this invention are further illustrated by the following examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this invention.

EXAMPLES

Preparation of 5-Iodo-1-(2-methylpropyl)-2-propyl-1*H*-imidazole-4-carbonitrile

Part A


Aminomalononitrile *p*-toluenesulfonate (744.65 g, 2.94 mol), triethylamine (297.5 g, 2.94 mol), and trimethyl orthobutyrate (436 g, 2.94 mol) were combined in toluene (7.45 L) and the solution was heated at 60 °C for 2.5 hours. Additional trimethyl orthobutyrate (21 g) was added, and the reaction was allowed to cool over a period of 30 minutes, and triethylamine (297.5 g, 2.94 mol) was added. The solution was further cooled to about 3 °C over 30 minutes, and isobutylamine (215.03 g, 2.94 mol) was added over a period of 90 minutes. During the addition, the reaction temperature rose to 10 °C. The reaction was warmed to room temperature slowly and stirred overnight. Deionized water (7.35 L) and sodium carbonate (735 g) were added over a period of 15 minutes while maintaining the temperature of the mixture at 20 °C with the addition of ice. The mixture was stirred for 15 minutes, and then the precipitate was isolated by filtration, washed sequentially with toluene (300 mL) and water (3 L), air-dried, and further dried under vacuum at 70 °C for 24 hours to provide 394.4 g (65%) of 5-amino-1-(2-methylpropyl)-2-propyl-1*H*-imidazole-4-carbonitrile as a beige solid, mp 134.5-136.5 °C.

Part B

A solution of isoamyl nitrite (106.3 g, 0.908 mol) and diiodomethane (1.296 kg, 4.84 mol) in chloroform (500 mL) was heated at 70 °C under a nitrogen atmosphere. A solution of 5-amino-1-(2-methylpropyl)-2-propyl-1*H*-imidazole-4-carbonitrile (50.0 g, 0.242 mol) in chloroform (500 mL) was heated to 70 °C and added over a period of 30 minutes while maintaining the reaction temperature at 68 °C to 70 °C during the addition. The reaction was heated for an additional 10 minutes, allowed to cool to room temperature, and concentrated under reduced pressure at 75 °C. The residue was purified by column chromatography on silica gel (eluting sequentially with dichloromethane, 1% methanol in dichloromethane, 2% methanol in dichloromethane, and 3% methanol in dichloromethane) to provide 39.4 g (51.3%) of 5-iodo-1-(2-methylpropyl)-2-propyl-1*H*-imidazole-4-carbonitrile as a tan oil that solidified upon standing.

Example 1

1-(2-Methylpropyl)-8-[2-(methylsulfonyl)ethyl]-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine



Part A

5 A 500 mL two-necked round bottom flask equipped with nitrogen inlet adaptor and magnetic stirring bar was charged with *tert*-butyl pyridin-4-ylcarbamate (3.88 g, 20.0 mmol, prepared as described in Spivey, A. C. *et al. J. Org. Chem.* 64, pp. 9430-9443 (1999)), *N,N,N',N'*-tetramethylethylenediamine (TMEDA) (8.15 mL, 54.0 mmol), and anhydrous tetrahydrofuran (THF) (10 mL). The resultant clear, colorless solution was

10 degassed with several cycles of evacuation under reduced pressure followed by a nitrogen purge, then cooled to -78°C with a dry ice/acetone bath. A solution of *n*-butyllithium in hexanes (20.0 mL of a 2.5 M solution, 50.0 mmol) was added via syringe under nitrogen atmosphere over 15 minutes (min), resulting in the formation of a thick tan slurry. After

15 10 min, the cooling bath was replaced with a 5°C ice bath, and the slurry was allowed to stir for 2 hours. The slurry was then cooled again to -78°C , and triisopropylborate (17.5 mL, 76.0 mmol) was added dropwise via syringe over 10 min. The reaction mixture was then warmed to ambient temperature and allowed to stir for 20 min. The reaction mixture initially became clear, and then a white precipitate formed. The resultant slurry was then

20 poured into saturated aqueous ammonium chloride (100 mL) and allowed to stir vigorously for an additional 20 min. The white precipitate was isolated by filtration, washed sequentially with water (100 mL) and diethyl ether (100 mL), and then dried overnight under reduced pressure, providing 3.10 g of 4-[(*tert*-butoxycarbonyl)amino]pyridin-3-ylboronic acid as a white solid.

Part B

25 A 100 mL round bottom flask was charged with 4-[(*tert*-butoxycarbonyl)amino]pyridin-3-ylboronic acid (2.38 g, 10.0 mmol) and ethanol (10 mL). To the clear, colorless solution was added a solution of hydrochloric acid in 1,4-dioxane

(10 mL of a 4.0 M solution, 40.0 mmol). Upon complete addition, the reaction mixture became warm, and a white precipitate formed. Additional ethanol (about 5 mL) was added until the reaction mixture became homogeneous. The flask was then fitted with a reflux condenser, and the solution was heated in a 90 °C oil bath. After 1 hour, the flask
5 was allowed to cool to ambient temperature, and most of the solvent was removed under reduced pressure. The remaining viscous oil was poured into diethyl ether (100 mL), using a small amount of methanol to assist in the transfer. A white precipitate formed immediately, and the resultant slurry was allowed to stir vigorously for 10 min. The precipitate was isolated by filtration and washed with an additional portion of diethyl ether
10 (50 mL). The collected solid was then dried under reduced pressure overnight, providing 1.74 g of 4-aminopyridin-3-ylboronic acid hydrochloride as a white solid.

Part C

A 500 mL round bottom flask was charged with 5-iodo-1-(2-methylpropyl)-2-propyl-1*H*-imidazole-4-carbonitrile (7.26 g, 22.9 mmol), 4-aminopyridin-3-ylboronic acid hydrochloride (4.40 g, 25.2 mmol), and *n*-propanol (150 mL). A solution of sodium carbonate (6.55 g, 3.44 mmol) in water (60 mL) was added, and nitrogen was bubbled
15 through the resultant solution for 15 min. Palladium (II) acetate (258 mg, 1.15 mmol) and triphenylphosphine (902 mg, 3.44 mmol) were added, and the solution was further degassed using several cycles of evacuation under reduced pressure followed by a nitrogen
20 purge. The solution was then heated at reflux under nitrogen atmosphere for 18 hours. After cooling to room temperature, the reaction mixture was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate, and the aqueous layer was extracted with additional portions of ethyl acetate. The combined organic layers were then washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced
25 pressure. The residue was purified via flash chromatography on silica gel (eluting with 7% methanol in dichloromethane) to afford 1.50 g of 1-(2-methylpropyl)-2-propyl-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine as a tan solid. Recrystallization from acetonitrile provided an analytically pure sample as white needles, mp 253-255 °C. MS (ESI) *m/z* 284 (*M* + *H*)⁺; Anal. Calcd for C₁₆H₂₁N₅: C, 66.76; H, 7.53; N, 24.33. Found:
30 C, 66.96; H, 7.44; N, 23.98.

Part D

A mixture of 1-(2-methylpropyl)-2-propyl-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine (1.50 g, 5.29 mmol), platinum oxide (1.0 g), and trifluoroacetic acid (20 mL) was placed under 50 psi (3.5×10^5 Pa) of hydrogen pressure on a Parr apparatus. After 14 hours, the mixture was diluted with dichloromethane (200 mL) and filtered through a pad of CELITE filter agent. The filtrate was concentrated under reduced pressure, and the residue was then dissolved in dichloromethane (100 mL) and water (100 mL). An aqueous 1 M sodium hydroxide solution was then added until a pH of 11-12 was reached. The organic layer was drawn off, and the aqueous layer was extracted with additional portions of dichloromethane (3 x 100 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to provide a tan solid. Crystallization from a mixture of acetonitrile and dichloromethane afforded 1.40 g of 1-(2-methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine as white needles.


Part E

To a solution of 1-(2-methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine (300 mg, 0.75 mmol) in THF (15 mL) was added triethylamine (0.37 mL, 2.6 mmol) and methyl vinyl sulfone (70 μ L, 0.82 mmol). The resultant slurry was allowed to stir for several hours at ambient temperature, after which time analysis by high pressure liquid chromatography (HPLC) indicated only partial conversion to the desired product. Additional triethylamine (0.37 mL, 2.6 mmol) was added, and the reaction mixture was heated at reflux for 14 hours. The reaction mixture was then partitioned between saturated aqueous sodium bicarbonate and dichloromethane, and the aqueous layer was extracted with additional portions of dichloromethane. The combined organic layers were dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via flash chromatography on silica gel (gradient elution with 5-10% methanol in dichloromethane) to afford 200 mg of 1-(2-methylpropyl)-8-[2-(methylsulfonyl)ethyl]-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine as a yellow solid, mp 82-84 °C. ^1H NMR (300 MHz, CDCl_3) δ 5.21 (br s, 2H), 3.96 (s, 2H), 3.91 (d, $J = 7.5$ Hz, 2H), 3.25 (t, $J = 6.0$ Hz, 2H), 3.12 (t, $J = 6.0$ Hz, 2H), 3.04 (s, 3H), 2.95 (t, $J = 5.4$ Hz, 2H), 2.87 (t, $J = 5.4$ Hz, 2H), 2.77 (t, $J = 7.5$ Hz, 2H), 2.02 (m, 1H), 1.87 (m, 2H), 1.04 (t, $J = 7.4$ Hz, 3H), 0.94 (d, $J = 6.7$ Hz, 6H);

MS (APCI) m/z 394 ($M + H$)⁺; Anal. calcd for C₁₉H₃₁N₅O₂S•0.5 H₂O: C, 56.69; H, 8.01; N, 17.40. Found: C, 56.61; H, 8.34; N, 17.38.

Example 2


5 1-(2-Methylpropyl)-8-(methylsulfonyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine



1-(2-Methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine (940 mg, 2.34 mmol, prepared as described in Part D of Example 1) was dissolved in dichloromethane (20 mL). Triethylamine (1.14 mL, 8.19 mmol) was added via syringe. The resultant solution was cooled in an ice bath, and methanesulfonyl chloride (0.18 mL, 2.34 mmol) was added via syringe. After 3 hours, the reaction solution was washed with saturated aqueous sodium bicarbonate (20 mL), dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via flash chromatography on silica gel (gradient elution with 3-8% methanol in dichloromethane) to afford 500 mg of 1-(2-methylpropyl)-8-(methylsulfonyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine as a white solid, mp 271-272 °C (dec.). ¹H NMR (300 MHz, CDCl₃) δ 5.03 (br s, 2H), 4.73 (s, 2H), 3.92 (d, *J* = 7.5 Hz, 2H), 3.67 (t, *J* = 6.1 Hz, 2H), 3.03 (t, *J* = 6.1 Hz, 2H), 2.87 (s, 3H), 2.78 (t, *J* = 7.6 Hz, 2H), 2.02 (pent, *J* = 6.8 Hz, 1H), 1.87 (m, 2H), 1.05 (t, *J* = 7.4 Hz, 3H), 0.97 (d, *J* = 6.8 Hz, 6H); MS (APCI) m/z 366 ($M + H$)⁺; Anal. calcd for C₁₇H₂₇N₅O₂S: C, 55.87; H, 7.45; N, 19.16. Found: C, 55.65; H, 7.65; N, 19.09.

Example 3


25 Ethyl 3-[4-amino-1-(2-methylpropyl)-2-propyl-1,6,7,9-tetrahydro-8*H*-imidazo[4,5-*c*]-1,6-naphthyridin-8-yl]propanoate



1-(2-Methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine (650 mg, 2.26 mmol, prepared as described in Part D of Example 1) was dissolved in THF (20 mL). Triethylamine (0.95 mL, 6.78 mmol) and ethyl acrylate (0.27 mL, 2.49 mmol) were added via syringe. The resultant solution was allowed to stir overnight at ambient temperature. The solution was then partitioned between dichloromethane and saturated aqueous sodium bicarbonate, and the aqueous layer was extracted with additional portions of dichloromethane. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified via flash chromatography on silica gel (gradient elution with 25-50% ethyl acetate in hexanes). Further purification was accomplished by trituration with diethyl ether to afford 300 mg of ethyl 3-(4-amino-1-(2-methylpropyl)-2-propyl-1,6,7,9-tetrahydro-8*H*-imidazo[4,5-*c*]-1,6-naphthyridin-8-yl)propanoate as a yellow solid, mp 109-110 °C. ¹H NMR (300 MHz, CDCl₃) δ 5.97 (br s, 2H), 4.08 (q, *J* = 7.1 Hz, 2H), 3.85 (d, *J* = 7.6 Hz, 2H), 3.81 (s, 2H), 2.94 (m, 2H), 2.86 (t, *J* = 7.2 Hz, 2H), 2.78-2.68 (m, 4H), 2.53 (t, *J* = 7.0 Hz, 2H), 1.98 (hextet, *J* = 7.0 Hz, 1H), 1.81 (hextet, *J* = 7.6 Hz, 2H), 1.19 (t, *J* = 7.1 Hz, 3H), 0.98 (t, *J* = 7.4 Hz, 3H), 0.89 (d, *J* = 7.0 Hz, 6H); MS (APCI) *m/z* 388 (M + H)⁺; Anal. calcd for C₂₁H₃₃N₅O₂•0.3 H₂O: C, 64.19; H, 8.62; N, 17.82. Found: C, 63.92; H, 8.38; N, 18.19.

Example 4


4-Amino-1-(2-methylpropyl)-*N*-phenyl-2-propyl-1,6,7,9-tetrahydro-8*H*-imidazo[4,5-*c*]-1,6-naphthyridine-8-carboxamide



1-(2-Methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]-1,6-naphthyridin-4-amine (500 mg, 1.74 mmol, prepared as described in Part D of Example 1) was dissolved in dichloromethane (15 mL). Triethylamine (0.73 mL, 5.22 mmol) and phenyl isocyanate (0.21 mL, 1.91 mmol) were added. The resultant solution was allowed to stir overnight at ambient temperature. The reaction solution was then partitioned between dichloromethane and saturated aqueous sodium bicarbonate, and the aqueous layer was extracted with additional portions of dichloromethane. The combined organic layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized from acetonitrile to afford 500 mg of 4-amino-1-(2-methylpropyl)-N-phenyl-2-propyl-1,6,7,9-tetrahydro-8H-imidazo[4,5-c]-1,6-naphthyridine-8-carboxamide as a white solid, mp 206-207 °C. ¹H NMR (300 MHz, CDCl₃) δ 7.19-7.07 (m, 4H), 6.85 (t, *J* = 7.3 Hz, 1H), 6.39 (br s, 1H), 4.92 (br s, 2H), 4.75 (s, 2H), 3.79 (d, *J* = 7.5 Hz, 2H), 3.55 (t, *J* = 6.1 Hz, 2H), 2.84 (t, *J* = 6.1 Hz, 2H), 2.58 (t, *J* = 7.5 Hz, 2H), 1.93-1.84 (m, 3H), 1.67 (hextet, *J* = 7.6 Hz, 2H), 0.85 (t, *J* = 7.4 Hz, 3H), 0.77 (d, *J* = 7.0 Hz, 6H); MS (APCI) *m/z* 407 (M + H)⁺; Anal. calcd for C₂₃H₃₀N₆O•0.3 H₂O: C, 67.06; H, 7.49; N, 20.40. Found: C, 66.72; H, 7.48; N, 20.24.

Example 5

1-(2-Methylpropyl)-7-(methylsulfonyl)-2-propyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]-1,7-naphthyridin-4-amine



Part A

A 250 mL round bottom flask equipped with magnetic stirring bar was charged with *N*⁵-(2-methylpropyl)tetraazolo[1,5-*a*]-1,7-naphthyridine-4,5-diamine (4.10 g, 16.0 mmol, Example 20 in U. S. Patent No. 6,194,425) and acetonitrile (80 mL). Butyryl chloride (1.80 mL, 17.6 mmol) was added via syringe, and the reaction solution was allowed to stir for 22 hours at ambient temperature. The solids were collected by filtration and washed with acetonitrile. The orange solid was utilized in the following step without further purification.

Part B

A 250 mL round bottom flask equipped with magnetic stirring bar was charged with the material from Part A (4.60 g, 12.6 mmol) and ethanol (18 mL, reagent grade). A solution of potassium carbonate (2.60 g, 19.0 mmol) in water (7 mL) was added, and the resultant reaction mixture was heated at reflux for 3 hours. The reaction mixture was then concentrated under reduced pressure, and the residue was partitioned between dichloromethane (50 mL) and water (30 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford the crude product. Purification by flash chromatography on silica gel (elution with 5% methanol in dichloromethane) provided 1.70 g of 6-(2-methylpropyl)-5-propyl-6*H*-imidazo[4,5-*c*]tetraazolo[1,5-*a*]-1,7-naphthyridine as an off-white solid.

Part C

A 500 mL round bottom flask equipped with magnetic stirring bar was charged with 6-(2-methylpropyl)-5-propyl-6*H*-imidazo[4,5-*c*]tetraazolo[1,5-*a*]-1,7-naphthyridine (1.50 g, 4.85 mmol) and 1,2-dichlorobenzene (24 mL). Triphenylphosphine (3.10 g, 11.6 mmol) was added all at once, and the resultant reaction mixture was heated at reflux for 3 hours. After cooling to ambient temperature, the mixture was diluted with hexanes (50 mL). The resultant suspension was allowed to stir overnight, and the solid was then collected by filtration and was washed with hexanes. The solid was suspended in methanol (24 mL) and 1 M aqueous hydrochloric acid (24 mL) was added. The resultant solution was heated at reflux for 3 hours, then concentrated under reduced pressure. A 50% aqueous sodium hydroxide solution was then added until a basic pH was reached. The solid that precipitated was collected by filtration and washing with water. Purification of this material by flash chromatography on silica gel (elution with 5% methanol in

dichloromethane) provided 1.0 g of 1-(2-methylpropyl)-2-propyl-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine as a white solid.

Part D

5 A mixture of 1-(2-methylpropyl)-2-propyl-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine (1.00 g, 3.53 mmol), platinum oxide (0.5 g), and trifluoroacetic acid (18 mL) was placed under 50 psi (3.5×10^5 Pa) of hydrogen pressure on a Parr apparatus. After 44 hours, the mixture was filtered through a pad of CELITE filter agent, washing with dichloromethane (100 mL). The filtrate was concentrated under reduced pressure, and the residue was dissolved in water (20 mL). The solution was adjusted to pH 12-13 with 50%
10 w/v aqueous sodium hydroxide solution. The product, 1-(2-methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine, was isolated by filtration, washed with water, dried, and used in the following step without further purification.


Part E

15 1-(2-Methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine (500 mg, 1.74 mmol) was dissolved in dichloromethane (7 mL). Triethylamine (0.40 mL, 2.6 mmol) was added, followed by methanesulfonyl chloride (0.14 mL, 1.8 mmol). The resultant solution was allowed to stir at ambient temperature for 1 hour. The reaction mixture was then concentrated under reduced pressure to afford a white solid that was purified by flash chromatography on silica gel (elution with 5%
20 methanol in dichloromethane). The product was then slurried in water (20 mL), and potassium carbonate was added until pH 10 was reached. The solid was isolated by filtration and dried under house vacuum at 65 °C for 18 hours to provide 0.40 g of 1-(2-methylpropyl)-7-(methylsulfonyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine as a white solid, mp 205-209 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ
25 5.74 (bs, 2H), 4.18 (s, 2H), 4.13 (d, *J* = 7.5 Hz, 2H), 3.45 (t, *J* = 5.6 Hz, 2H), 2.94 (s, 3H), 2.92-2.91 (m, 2H), 2.79 (t, *J* = 7.5 Hz, 2H), 2.06 (pentet, *J* = 6.9 Hz, 1H), 1.79 (sextet, *J* = 7.5 Hz, 2H), 0.98 (t, *J* = 7.5 Hz, 3H), 0.80 (t, *J* = 6.9 Hz, 6H); MS (APCI) *m/z* 366 (*M* + *H*)⁺; Anal. calcd for C₁₇H₂₇N₅O₂S: C, 55.87; H, 7.45; N, 19.16. Found: C, 55.65; H, 7.68; N, 19.14.

30

Example 6

1-(2-Methylpropyl)-7-[2-(methylsulfonyl)ethyl]-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine



5 1-(2-Methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine (450 mg, 1.57 mmol, prepared in step F of Example 5) was dissolved in THF (6 mL). Methyl vinyl sulfone (180 mg, 1.72 mmol) was added via syringe to the solution. The reaction mixture was heated at reflux for 1.5 hours, and then was concentrated under reduced pressure. The residue was purified by flash
10 chromatography on silica gel (eluted with 10% methanol in dichloromethane) to afford a white solid that was crystallized from ethyl acetate to give 350 mg of 1-(2-methylpropyl)-7-[2-(methylsulfonyl)ethyl]-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,7-naphthyridin-4-amine as white crystals, mp 169-170 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 5.57 (bs, 2H), 4.11 (d, *J* = 7.5 Hz, 2H), 3.49 (s, 2H), 3.39 (t, *J* = 6.9 Hz, 2H), 3.02 (s,
15 3H), 2.90 (t, *J* = 6.9 Hz, 2H), 2.82-2.74 (m, 6H), 2.07 (pentet, *J* = 6.9 Hz, 1H), 1.78 (sextet, *J* = 7.5 Hz, 2H), 0.98 (t, *J* = 7.5 Hz, 3H), 0.80 (t, *J* = 6.9 Hz, 6H); MS (APCI) *m/z* 394 (M + H)⁺; Anal. calcd for C₁₉H₃₁N₅O₂S: C, 57.99; H, 7.94; N, 17.80. Found: C, 58.18; H, 8.17; N, 18.11.

20







Examples 7-31











A mixture of 1-(2-methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine (1.3 g, 4.5 mmol, prepared as described in Part D of Example 1) and *N,N*-diisopropylethylamine (1.6 mL, 9.0 mmol) was diluted with chloroform to yield 45 mL of a solution. The solution (1 mL) was added to a test tube containing a reagent
25 from the table below (1.1 equivalents, 0.11 mmol). The test tube was capped and placed on a shaker at ambient temperature overnight (approximately 18 hours). Water (50 μL) was added to each tube. The solvent was removed by vacuum centrifugation. The compounds were purified by reversed phase preparative high-performance liquid










chromatography (prep HPLC) using a Waters FractionLynx automated purification system. The prep HPLC fractions were analyzed using a Waters LC/TOF-MS, and the appropriate fractions were centrifuge evaporated to provide the trifluoroacetate salt of the desired compound. Reversed phase preparative liquid chromatography was performed with non-linear gradient elution from 5-95% B where A is 0.05% trifluoroacetic acid/water and B is 0.05% trifluoroacetic acid/acetonitrile. Fractions were collected by mass-selective triggering. The table below shows the acylating agent used for each example, the structure of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.


10

Examples 7-31

			
Example	Reagent	R	Measured Mass (M+H)
7	Methyl chloroformate		346.2235
8	Cyclopropanecarbonyl chloride		356.2473
9	Isobutyryl chloride		358.2621
10	Benzoyl chloride		392.2490
11	4-Fluorobenzoyl chloride		410.2371

12	Hydrocinnamoyl chloride		420.2791
13	3-Methoxybenzoyl chloride		422.2574
14	<i>p</i> -Anisoyl chloride		422.2592
15	Ethanesulfonyl chloride		380.2158
16	Isopropylsulfonyl chloride		394.2283
17	Dimethylsulfamoyl chloride		395.2262
18	Benzenesulfonyl chloride		428.2137
19	<i>alpha</i> -Toluenesulfonyl chloride		442.2297
20	4-Fluorobenzenesulfonyl chloride		446.2056
21	3-Methoxybenzenesulfonyl chloride		458.2232




22	4-Methoxybenzenesulfonyl chloride		458.2253
23	Methyl isocyanate		345.2396
24	Ethyl isocyanate		359.2568
25	Isopropyl isocyanate		373.2735
26	Cyclopentyl isocyanate		399.2870
27	Phenyl isocyanate		407.2593
28	4-Fluorophenyl isocyanate		425.2509
29	3-Methoxyphenyl isocyanate		437.2704
30	<i>N,N</i> -Dimethylcarbamoyl chloride		359.2555






31	<i>N</i> -Methyl- <i>N</i> -phenylcarbamoyl chloride		421.2748
----	--	--	----------

Examples 32-38

1-(2-Methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine (862 mg, 3.0 mmol, prepared as described in Part D of Example 1) was diluted with methanol to provide 30 mL of solution. The solution (1 mL) was added to a test tube containing an aldehyde or ketone (1.25 equivalents, 0.125 mmol) from the table below. The test tubes were capped and vortexed for 15 minutes. Borane-pyridine complex (16 μ L, 0.13 mmol, 1.3 eq) was added to each tube, which was then vortexed overnight (approximately 18 hours). Water (50 μ L) was added to each tube. The solvent was removed by vacuum centrifugation. The compounds were purified as described for Examples 7-31. The table below shows the aldehyde or ketone used for each example, the structure of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.

Examples 32-38





			
Example	Reagent	R	Measured Mass (M+H)
32	Benzaldehyde		378.2643
33	2-Fluorobenzaldehyde		396.2565

34	3-Fluorobenzaldehyde		396.2549
35	4-Fluorobenzaldehyde		396.2549
36	3-Phenylpropionaldehyde		406.2998
37	<i>o</i> -Anisaldehyde		408.2786
38	Dihydroxyacetone		362.2570

Examples 39-41

1-(2-Methylpropyl)-2-propyl-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]-1,6-naphthyridin-4-amine (260 mg, 0.90 mmol, prepared as described in Part D of Example 1) was diluted with THF to provide 9 mL of solution. The solution (1 mL) was added to a test tube containing a reagent (1 equivalent, 0.1 mmol) from the table below. The test tube was capped and stirred for 116 hours at 70 °C. The solvent was removed by vacuum centrifugation. The compounds were purified as described for Examples 7-31. The table below shows the reagent used for each example, the structure of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.


Examples 39-41

			
Example	Reagent	R	Measured Mass (M+H)
39	2-Cyclohexene-1-one		384.2795
40	Methyl vinyl sulfone		394.2290
41	Ethyl vinyl sulfone		408.2449


5 Exemplary Compounds

Certain exemplary compounds, including some of those described above in the Examples, have the following Formula (IIa or IIIa) and one R₁, one R₂, and one R₃ substituent shown in the following table, wherein each line of the table is matched with the Formula (IIa or IIIa) to represent a specific embodiment of the invention.

10



IIa



IIIa

R ₁	R ₂	R ₃
2-hydroxy-2-methylpropyl	methyl	benzyl
2-methylpropyl	methyl	benzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	methyl	benzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	methyl	benzyl
2-hydroxy-2-methylpropyl	propyl	benzyl
2-methylpropyl	propyl	benzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	propyl	benzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	propyl	benzyl
2-hydroxy-2-methylpropyl	hydroxymethyl	benzyl
2-methylpropyl	hydroxymethyl	benzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	hydroxymethyl	benzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	hydroxymethyl	benzyl
2-hydroxy-2-methylpropyl	ethoxymethyl	benzyl
2-methylpropyl	ethoxymethyl	benzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	ethoxymethyl	benzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	ethoxymethyl	benzyl
2-hydroxy-2-methylpropyl	methyl	pyridin-3-ylmethyl
2-methylpropyl	methyl	pyridin-3-ylmethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	methyl	pyridin-3-ylmethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	methyl	pyridin-3-ylmethyl

2-hydroxy-2-methylpropyl	propyl	pyridin-3-ylmethyl
2-methylpropyl	propyl	pyridin-3-ylmethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	propyl	pyridin-3-ylmethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	propyl	pyridin-3-ylmethyl
2-hydroxy-2-methylpropyl	hydroxymethyl	pyridin-3-ylmethyl
2-methylpropyl	hydroxymethyl	pyridin-3-ylmethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	hydroxymethyl	pyridin-3-ylmethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	hydroxymethyl	pyridin-3-ylmethyl
2-hydroxy-2-methylpropyl	ethoxymethyl	pyridin-3-ylmethyl
2-methylpropyl	ethoxymethyl	pyridin-3-ylmethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	ethoxymethyl	pyridin-3-ylmethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	ethoxymethyl	pyridin-3-ylmethyl
2-hydroxy-2-methylpropyl	methyl	4-fluorobenzyl
2-methylpropyl	methyl	4-fluorobenzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	methyl	4-fluorobenzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	methyl	4-fluorobenzyl
2-hydroxy-2-methylpropyl	propyl	4-fluorobenzyl
2-methylpropyl	propyl	4-fluorobenzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	propyl	4-fluorobenzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	propyl	4-fluorobenzyl
2-hydroxy-2-methylpropyl	hydroxymethyl	4-fluorobenzyl

2-methylpropyl	hydroxymethyl	4-fluorobenzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	hydroxymethyl	4-fluorobenzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	hydroxymethyl	4-fluorobenzyl
2-hydroxy-2-methylpropyl	ethoxymethyl	4-fluorobenzyl
2-methylpropyl	ethoxymethyl	4-fluorobenzyl
2-methyl-2- [(methylsulfonyl)amino]propyl	ethoxymethyl	4-fluorobenzyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	ethoxymethyl	4-fluorobenzyl
2-hydroxy-2-methylpropyl	methyl	methylsulfonyl
2-methylpropyl	methyl	methylsulfonyl
2-methyl-2- [(methylsulfonyl)amino]propyl	methyl	methylsulfonyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	methyl	methylsulfonyl
2-hydroxy-2-methylpropyl	propyl	methylsulfonyl
2-methylpropyl	propyl	methylsulfonyl
2-methyl-2- [(methylsulfonyl)amino]propyl	propyl	methylsulfonyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	propyl	methylsulfonyl
2-hydroxy-2-methylpropyl	hydroxymethyl	methylsulfonyl
2-methylpropyl	hydroxymethyl	methylsulfonyl
2-methyl-2- [(methylsulfonyl)amino]propyl	hydroxymethyl	methylsulfonyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	hydroxymethyl	methylsulfonyl
2-hydroxy-2-methylpropyl	ethoxymethyl	methylsulfonyl
2-methylpropyl	ethoxymethyl	methylsulfonyl

2-methyl-2- [(methylsulfonyl)amino]propyl	ethoxymethyl	methylsulfonyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	ethoxymethyl	methylsulfonyl
2-hydroxy-2-methylpropyl	methyl	2-(methylsulfonyl)ethyl
2-methylpropyl	methyl	2-(methylsulfonyl)ethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	methyl	2-(methylsulfonyl)ethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	methyl	2-(methylsulfonyl)ethyl
2-hydroxy-2-methylpropyl	propyl	2-(methylsulfonyl)ethyl
2-methylpropyl	propyl	2-(methylsulfonyl)ethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	propyl	2-(methylsulfonyl)ethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	propyl	2-(methylsulfonyl)ethyl
2-hydroxy-2-methylpropyl	hydroxymethyl	2-(methylsulfonyl)ethyl
2-methylpropyl	hydroxymethyl	2-(methylsulfonyl)ethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	hydroxymethyl	2-(methylsulfonyl)ethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	hydroxymethyl	2-(methylsulfonyl)ethyl
2-hydroxy-2-methylpropyl	ethoxymethyl	2-(methylsulfonyl)ethyl
2-methylpropyl	ethoxymethyl	2-(methylsulfonyl)ethyl
2-methyl-2- [(methylsulfonyl)amino]propyl	ethoxymethyl	2-(methylsulfonyl)ethyl
tetrahydro-2 <i>H</i> -pyran-4- ylmethyl	ethoxymethyl	2-(methylsulfonyl)ethyl
2-hydroxy-2-methylpropyl	methyl	phenylaminocarbonyl
2-methylpropyl	methyl	phenylaminocarbonyl
2-methyl-2-	methyl	phenylaminocarbonyl

[(methylsulfonyl)amino]propyl		
tetrahydro-2 <i>H</i> -pyran-4-ylmethyl	methyl	phenylaminocarbonyl
2-hydroxy-2-methylpropyl	propyl	phenylaminocarbonyl
2-methylpropyl	propyl	phenylaminocarbonyl
2-methyl-2-[(methylsulfonyl)amino]propyl	propyl	phenylaminocarbonyl
tetrahydro-2 <i>H</i> -pyran-4-ylmethyl	propyl	phenylaminocarbonyl
2-hydroxy-2-methylpropyl	hydroxymethyl	phenylaminocarbonyl
2-methylpropyl	hydroxymethyl	phenylaminocarbonyl
2-methyl-2-[(methylsulfonyl)amino]propyl	hydroxymethyl	phenylaminocarbonyl
tetrahydro-2 <i>H</i> -pyran-4-ylmethyl	hydroxymethyl	phenylaminocarbonyl
2-hydroxy-2-methylpropyl	ethoxymethyl	phenylaminocarbonyl
2-methylpropyl	ethoxymethyl	phenylaminocarbonyl
2-methyl-2-[(methylsulfonyl)amino]propyl	ethoxymethyl	phenylaminocarbonyl
tetrahydro-2 <i>H</i> -pyran-4-ylmethyl	ethoxymethyl	phenylaminocarbonyl

Compounds of the invention have been found to modulate cytokine biosynthesis by inducing the production of interferon α and/or tumor necrosis factor α in human cells when tested using one of the methods described below.

CYTOKINE INDUCTION IN HUMAN CELLS

An in vitro human blood cell system is used to assess cytokine induction. Activity is based on the measurement of interferon (α) and tumor necrosis factor (α) (IFN- α and TNF- α , respectively) secreted into culture media as described by Testerman et. al. in

"Cytokine Induction by the Immunomodulators Imiquimod and S-27609", *Journal of Leukocyte Biology*, 58, 365-372 (September, 1995).

Blood Cell Preparation for Culture

5 Whole blood from healthy human donors is collected by venipuncture into vacutainer tubes or syringes containing EDTA. Peripheral blood mononuclear cells (PBMC) are separated from whole blood by density gradient centrifugation using HISTOPAQUE-1077 (Sigma, St. Louis, MO) or Ficoll-Paque Plus (Amersham Biosciences Piscataway, NJ). Blood is diluted 1:1 with Dulbecco's Phosphate Buffered Saline (DPBS) or Hank's Balanced Salts Solution (HBSS). Alternately, whole blood is
10 placed in Accuspin (Sigma) or LeucoSep (Greiner Bio-One, Inc., Longwood, FL) centrifuge frit tubes containing density gradient medium. The PBMC layer is collected and washed twice with DPBS or HBSS and re-suspended at 4×10^6 cells/mL in RPMI complete. The PBMC suspension is added to 96 well flat bottom sterile tissue culture
15 plates containing an equal volume of RPMI complete media containing test compound.

Compound Preparation

 The compounds are solubilized in dimethyl sulfoxide (DMSO). The DMSO concentration should not exceed a final concentration of 1% for addition to the culture wells. The compounds are generally tested at concentrations ranging from 30-0.014 μ M.
20 Controls include cell samples with media only, cell samples with DMSO only (no compound), and cell samples with reference compound.

Incubation

 The solution of test compound is added at 60 μ M to the first well containing RPMI complete and serial 3 fold dilutions are made in the wells. The PBMC suspension is then
25 added to the wells in an equal volume, bringing the test compound concentrations to the desired range (usually 30-0.014 μ M). The final concentration of PBMC suspension is 2×10^6 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37°C in a 5% carbon dioxide atmosphere.

Separation

30 Following incubation the plates are centrifuged for 10 minutes at 1000 rpm (approximately 200 x g) at 4°C. The cell-free culture supernatant is removed and transferred to sterile polypropylen tubes. Samples are maintained at -30 to -70°C until

analysis. The samples are analyzed for IFN- α by ELISA and for TNF- α by IGEN/BioVeris Assay.

Interferon (α) and Tumor Necrosis Factor (α) Analysis

IFN- α concentration is determined with a human multi-subtype colorimetric sandwich ELISA (Catalog Number 41105) from PBL Biomedical Laboratories, Piscataway, NJ. Results are expressed in pg/mL.

The TNF- α concentration is determined by ORIGEN M-Series Immunoassay and read on an IGEN M-8 analyzer from BioVeris Corporation, formerly known as IGEN International, Gaithersburg, MD. The immunoassay uses a human TNF- α capture and detection antibody pair (Catalog Numbers AHC3419 and AHC3712) from Biosource International, Camarillo, CA. Results are expressed in pg/mL.

Assay Data and Analysis

In total, the data output of the assay consists of concentration values of TNF- α and IFN- α (y-axis) as a function of compound concentration (x-axis).

Analysis of the data has two steps. First, the greater of the mean DMSO (DMSO control wells) or the experimental background (usually 20 pg/mL for IFN- α and 40 pg/mL for TNF- α) is subtracted from each reading. If any negative values result from background subtraction, the reading is reported as " * ", and is noted as not reliably detectable. In subsequent calculations and statistics, " * ", is treated as a zero. Second, all background subtracted values are multiplied by a single adjustment ratio to decrease experiment to experiment variability. The adjustment ratio is the area of the reference compound in the new experiment divided by the expected area of the reference compound based on the past 61 experiments (unadjusted readings). This results in the scaling of the reading (y-axis) for the new data without changing the shape of the dose-response curve. The reference compound used is 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethanol hydrate (U.S. Patent No. 5,352,784; Example 91) and the expected area is the sum of the median dose values from the past 61 experiments.

The minimum effective concentration is calculated based on the background-subtracted, reference-adjusted results for a given experiment and compound. The minimum effective concentration (μ molar) is the lowest of the tested compound concentrations that induces a response over a fixed cytokine concentration for the tested

cytokine (usually 20 pg/mL for IFN- α and 40 pg/mL for TNF- α). The maximal response is the maximal amount of cytokine (pg/ml) produced in the dose-response.

CYTOKINE INDUCTION IN HUMAN CELLS

5 (High Throughput Screen)

The CYTOKINE INDUCTION IN HUMAN CELLS test method described above was modified as follows for high throughput screening.

Blood Cell Preparation for Culture

10 Whole blood from healthy human donors is collected by venipuncture into vacutainer tubes or syringes containing EDTA. Peripheral blood mononuclear cells (PBMC) are separated from whole blood by density gradient centrifugation using HISTOPAQUE-1077 (Sigma, St. Louis, MO) or Ficoll-Paque Plus (Amersham Biosciences Piscataway, NJ). Whole blood is placed in Accuspin (Sigma) or LeucoSep
15 (Greiner Bio-One, Inc., Longwood, FL) centrifuge frit tubes containing density gradient medium. The PBMC layer is collected and washed twice with DPBS or HBSS and re-suspended at 4×10^6 cells/mL in RPMI complete (2-fold the final cell density). The PBMC suspension is added to 96-well flat bottom sterile tissue culture plates.

Compound Preparation

20 The compounds are solubilized in dimethyl sulfoxide (DMSO). The compounds are generally tested at concentrations ranging from 30 - 0.014 μ M. Controls include cell samples with media only, cell samples with DMSO only (no compound), and cell samples with a reference compound 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro- α,α -dimethyl-1H-imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Patent No. 5,352,784; Example 91)
25 on each plate. The solution of test compound is added at 7.5 mM to the first well of a dosing plate and serial 3 fold dilutions are made for the 7 subsequent concentrations in DMSO. RPMI Complete media is then added to the test compound dilutions in order to reach a final compound concentration of 2-fold higher (60 - 0.028 μ M) than the final tested concentration range.

30 Incubation

Compound solution is then added to the wells containing the PBMC suspension bringing the test compound concentrations to the desired range (usually 30 - 0.014 μ M)

and the DMSO concentration to 0.4 %. The final concentration of PBMC suspension is 2×10^6 cells/mL. The plates are covered with sterile plastic lids, mixed gently and then incubated for 18 to 24 hours at 37°C in a 5% carbon dioxide atmosphere.

Separation

5 Following incubation the plates are centrifuged for 10 minutes at 1000 rpm (approximately 200 g) at 4°C. 4-plex Human Panel MSD MULTI-SPOT 96-well plates are pre-coated with the appropriate capture antibodies by MesoScale Discovery, Inc. (MSD, Gaithersburg, MD). The cell-free culture supernatants are removed and transferred to the MSD plates. Fresh samples are typically tested, although they may be maintained at
10 -30 to -70°C until analysis.

Interferon- α and Tumor Necrosis Factor- α Analysis

MSD MULTI-SPOT plates contain within each well capture antibodies for human TNF- α and human IFN- α that have been pre-coated on specific spots. Each well contains four spots: one human TNF- α capture antibody (MSD) spot, one human IFN- α capture
15 antibody (PBL Biomedical Laboratories, Piscataway, NJ) spot, and two inactive bovine serum albumin spots. The human TNF- α capture and detection antibody pair is from MesoScale Discovery. The human IFN- α multi-subtype antibody (PBL Biomedical Laboratories) captures all IFN- α subtypes except IFN- α F (IFNA21). Standards consist of recombinant human TNF- α (R&D Systems, Minneapolis, MN) and IFN- α (PBL
20 Biomedical Laboratories). Samples and separate standards are added at the time of analysis to each MSD plate. Two human IFN- α detection antibodies (Cat. Nos. 21112 & 21100, PBL) are used in a two to one ratio (weight:weight) to each other to determine the IFN- α concentrations. The cytokine-specific detection antibodies are labeled with the SULFO-TAG reagent (MSD). After adding the SULFO-TAG labeled detection antibodies
25 to the wells, each well's electrochemoluminescent levels are read using MSD's SECTOR HTS READER. Results are expressed in pg/mL upon calculation with known cytokine standards.

Assay Data and Analysis

In total, the data output of the assay consists of concentration values of TNF- α or
30 IFN- α (y-axis) as a function of compound concentration (x-axis).

A plate-wise scaling is performed within a given experiment aimed at reducing plate-to-plate variability associated within the same experiment. First, the greater of the

median DMSO (DMSO control wells) or the experimental background (usually 20 pg/mL for IFN- α and 40 pg/mL for TNF- α) is subtracted from each reading. Negative values that may result from background subtraction are set to zero. Each plate within a given experiment has a reference compound that serves as a control. This control is used to calculate a median expected area under the curve across all plates in the assay. A plate-wise scaling factor is calculated for each plate as a ratio of the area of the reference compound on the particular plate to the median expected area for the entire experiment. The data from each plate are then multiplied by the plate-wise scaling factor for all plates. Only data from plates bearing a scaling factor of between 0.5 and 2.0 (for both cytokines IFN- α , TNF- α) are reported. Data from plates with scaling factors outside the above mentioned interval are retested until they bear scaling factors inside the above mentioned interval. The above method produces a scaling of the y-values without altering the shape of the curve. The reference compound used is 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethanol hydrate (U.S. Patent No. 5,352,784; Example 91). The median expected area is the median area across all plates that are part of a given experiment.


A second scaling may also be performed to reduce inter-experiment variability (across multiple experiments). All background-subtracted values are multiplied by a single adjustment ratio to decrease experiment-to-experiment variability. The adjustment ratio is the area of the reference compound in the new experiment divided by the expected area of the reference compound based on an average of previous experiments (unadjusted readings). This results in the scaling of the reading (y-axis) for the new data without changing the shape of the dose-response curve. The reference compound used is 2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro- α,α -dimethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethanol hydrate (U.S. Patent No. 5,352,784; Example 91) and the expected area is the sum of the median dose values from an average of previous experiments.

The minimum effective concentration is calculated based on the background-subtracted, reference-adjusted results for a given experiment and compound. The minimum effective concentration (μ molar) is the lowest of the tested compound concentrations that induces a response over a fixed cytokine concentration for the tested cytokine (usually 20 pg/mL for IFN- α and 40 pg/mL for TNF- α). The maximal response is the maximal amount of cytokine (pg/ml) produced in the dose-response.

The complete disclosures of the patents, patent documents, and publications cited herein are incorporated by reference in their entirety as if each were individually
5 incorporated. Various modifications and alterations to this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention. It should be understood that this invention is not intended to be unduly limited by the illustrative embodiments and examples set forth herein and that such examples and
10 embodiments are presented by way of example only with the scope of the invention intended to be limited only by the claims set forth herein as follows.

WHAT IS CLAIMED IS:


1. A compound selected from the group consisting of Formulas I, II, III, and IV:




wherein:

R₃ is selected from the group consisting of:

-Q-R₄,



-Z-Ar,



-X-Y-R₄,

-X-R₅,

-alkylenc-CH(CH₂-OH)-OH,

-alkylene-CH(CH₂CH₂-OH)-OH, and

-(alkylene)_{0.1}-CH(CH₂OH)₂;

Q is selected from the group consisting of -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-,

-C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene, wherein the alkylene, alkenylene, and alkynylene groups are optionally interrupted by one or more -O- groups;

Ar is selected from the group consisting of aryl and heteroaryl each of which is
 5 unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, cyano, amino, alkylamino, and dialkylamino;

D is CH or N; with the proviso that when D is N, then Q is -C(R₆)- or -S(O)₂-;

E is selected from the group consisting of -O-, -C(O)-, -S(O)_{0.2}-, and -N(Q₁-R₄)-;

10 R is selected from the group consisting of alkyl, alkoxy, fluoro, hydroxy, and trifluoromethyl;

n is 0, 1, or 2;


R₁ is selected from the group consisting of:

15 -R₄,
 -X-R₄,
 -X-Y-R₄,
 -X-Y-X-Y-R₄,
 -X-R₅,
 -N(R₁')-Q₁-R₄,
 20 -D'-X₁-Y₁-R₄, and
 -D'-X₁-R_{5a};


D' is selected from the group consisting of -N(R₁')- and -O-;

R₁' is selected from the group consisting of hydrogen, C₁₋₂₀ alkyl, hydroxyC₂₋₂₀ alkyl, and alkoxyC₂₋₂₀ alkyl;


25 X₁ is C₂₋₂₀ alkylene with the proviso that when Y₁ is -C(R₆)-N(R₈)- or



Y₁ is selected from the group consisting of -O-, -S(O)_{0.2}-, -S(O)₂-N(R₈)-,



R_{5a} is selected from the group consisting of:




R₂ is selected from the group consisting of:

-R₄,
 -X-R₄,
 -X-Y-R₄,
 -X-R₅,
 -OH,
 -NH₂, and
 -NH-Q₂-R₄;

X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

Y is selected from the group consisting of:

-O-,
 -S(O)₀₋₂-,
 -S(O)₂-N(R₈)-,
 -C(R₆)-,
 -C(R₆)-O-,
 -O-C(R₆)-,
 -O-C(O)-O-,
 -N(R₈)-Q₁-,
 -C(R₆)-N(R₈)-,
 -O-C(R₆)-N(R₈)-,
 -C(R₆)-N(OR₉)-,
 -O-N(R₈)-Q₁-,
 -O-N=C(R₄)-,
 -C(=N-O-R₈)-,
 -CH(-N(-O-R₈)-Q₁-R₄)-,




5

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl; alkoxy; hydroxyalkyl; haloalkyl; haloalkoxy; halogen; nitro; hydroxy; mercapto; cyano; aryl; aryloxy; arylalkyleneoxy; heteroaryl; heteroaryloxy; heteroarylalkyleneoxy; heterocyclyl; amino; alkylamino; dialkylamino; (dialkylamino)alkyleneoxy; and, in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

10

15

R_5 is selected from the group consisting of:




20

R_6 is selected from the group consisting of $=\text{O}$ and $=\text{S}$;

- R_7 is C_{2-7} alkylene;
 R_{8a} is selected from the group consisting of hydrogen and C_{1-4} alkyl;
 R_8 is selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxyalkylenyl, alkoxyalkylenyl, arylalkylenyl, and heteroarylalkylenyl;
 5 R_9 is selected from the group consisting of hydrogen and alkyl;
 R_{10} is C_{3-8} alkylene;
 A is selected from the group consisting of $-CH_2-$, $-O-$, $-C(O)-$, $-S(O)_{0-2}-$, and $-N(-Q_1-R_4)-$;
 A' is selected from the group consisting of $-O-$, $-S(O)_{0-2}-$, $-N(-Q_1-R_4)-$, and $-CH_2-$;
 10 Q_1 is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_8)-W-$, $-S(O)_2-N(R_8)-$, $-C(R_6)-O-$, $-C(R_6)-S-$, and $-C(R_6)-N(OR_9)-$;
 Q_2 is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_{8a})-W-$, $-S(O)_2-N(R_{8a})-$, and $-C(R_6)-O-$;
 V is selected from the group consisting of a bond, $-C(R_6)-$, $-O-C(R_6)-$,
 15 $-N(R_8)-C(R_6)-$, and $-S(O)_2-$;
 W is selected from the group consisting of a bond, $-C(O)-$, and $-S(O)_2-$; and
 a and b are independently integers from 1 to 6 with the proviso that $a + b \leq 7$;
 or a pharmaceutically acceptable salt thereof.


- 20 2. The compound or salt of claim 1 wherein the compound is of the Formula II:



II

or a pharmaceutically acceptable salt thereof.


- 25 3. The compound or salt of claim 1 wherein the compound is of the Formula III:



III

or a pharmaceutically acceptable salt thereof.


- 5 4. A compound selected from the group consisting of the Formulas V, VI, VII, and VIII:



V

VI

VII



VIII

wherein:

G is selected from the group consisting of:

- C(O)-R',
- α -aminoacyl,
- 15 α -aminoacyl- α -aminoacyl,
- C(O)-O-R',
- C(O)-N(R'')R',
- C(=NY')-R',
- CH(OH)-C(O)-OY',
- 20 -CH(OC₁₋₄ alkyl)Y₀,
- CH₂Y₂, and



R' and R'' are independently selected from the group consisting of C₁₋₁₀ alkyl, C₃₋₇ cycloalkyl, phenyl, benzyl, and 2-phenylethyl, each of which may be unsubstituted or substituted by one or more substituents independently selected from the group consisting of halogen, hydroxy, nitro, cyano, carboxy, C₁₋₆ alkyl, C₁₋₄ alkoxy, aryl, heteroaryl, aryl-C₁₋₄ alkylenyl, heteroaryl-C₁₋₄ alkylenyl, halo-C₁₋₄ alkylenyl, halo-C₁₋₄ alkoxy, -O-C(O)-CH₃, -C(O)-O-CH₃, -C(O)-NH₂, -O-CH₂-C(O)-NH₂, -NH₂, and -S(O)₂-NH₂, with the proviso that R'' can also be hydrogen;






α-aminoacyl is an α-aminoacyl group derived from an α-amino acid selected from the group consisting of racemic, D-, and L-amino acids;

Y' is selected from the group consisting of hydrogen, C₁₋₆ alkyl, and benzyl;

Y₀ is selected from the group consisting of C₁₋₆ alkyl, carboxy-C₁₋₆ alkylenyl, amino-C₁₋₄ alkylenyl, mono-*N*-C₁₋₆ alkylamino-C₁₋₄ alkylenyl, and di-*N,N*-C₁₋₆ alkylamino-C₁₋₄ alkylenyl;

Y₂ is selected from the group consisting of mono-*N*-C₁₋₆ alkylamino, di-*N,N*-C₁₋₆ alkylamino, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, and 4-C₁₋₄ alkylpiperazin-1-yl;

R₃ is selected from the group consisting of:



Q is selected from the group consisting of -C(R₆)-, -C(R₆)-C(R₆)-, -S(O)₂-, -C(R₆)-N(R₈)-W-, -S(O)₂-N(R₈)-, -C(R₆)-O-, -C(R₆)-S-, and -C(R₆)-N(OR₉)-;

Z is selected from the group consisting of a bond, alkylene, alkenylene, and alkynylene, wherein the alkylene, alkenylene, and alkynylene groups are optionally interrupted by one or more -O- groups;

Ar is selected from the group consisting of aryl and heteroaryl each of which is unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkoxy, methylenedioxy, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, hydroxyalkyl, cyano, amino, alkylamino, and dialkylamino;

D is CH or N; with the proviso that when D is N, then Q is -C(R₆)- or -S(O)₂-;

E is selected from the group consisting of -O-, -C(O)-, -S(O)₀₋₂-, and -N(Q₁-R₄)-;

R is selected from the group consisting of alkyl, alkoxy, fluoro, hydroxy, and trifluoromethyl;

n is 0, 1, or 2;


R₁ is selected from the group consisting of:

-R₄,
 -X-R₄,
 -X-Y-R₄,
 -X-Y-X-Y-R₄,
 -X-R₅,
 -N(R₁')-Q₁-R₄,
 -D'-X₁-Y₁-R₄, and
 -D'-X₁-R_{5a};

D' is selected from the group consisting of -N(R₁')- and -O-;

R₁' is selected from the group consisting of hydrogen, C₁₋₂₀ alkyl, hydroxyC₂₋₂₀ alkyl, and alkoxyC₂₋₂₀ alkyl;


X₁ is C₂₋₂₀ alkylene with the proviso that when Y₁ is -C(R₆)-N(R₈)- or



Y₁ is selected from the group consisting of -O-, -S(O)₀₋₂-, -S(O)₂-N(R₈)-,

-N(R₈)-Q₁-, -C(R₆)-N(R₈)-, -O-C(R₆)-N(R₈)-, and $\text{---V---N} \begin{array}{c} \text{---} \\ \text{R}_{10} \end{array} \text{---};$

R_{5a} is selected from the group consisting of:




R₂ is selected from the group consisting of:

- R₄,
- X-R₄,
- X-Y-R₄,
- X-R₅,
- OH,
- NH₂, and
- NH-Q₂-R₄;

X is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;

Y is selected from the group consisting of:

- O-,
- S(O)₀₋₂-,
- S(O)₂-N(R₈)-,
- C(R₆)-,
- C(R₆)-O-,
- O-C(R₆)-,
- O-C(O)-O-,
- N(R₈)-Q₁-,
- C(R₆)-N(R₈)-,
- O-C(R₆)-N(R₈)-,
- C(R₆)-N(OR₉)-,
- O-N(R₈)-Q₁-,
- O-N=C(R₄)-,
- C(=N-O-R₈)-,
- CH(-N(-O-R₈)-Q₁-R₄)-,




5

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl; alkoxy; hydroxyalkyl; haloalkyl; haloalkoxy; halogen; nitro; hydroxy; mercapto; cyano; aryl; aryloxy; arylalkyleneoxy; heteroaryl; heteroaryloxy; heteroarylalkyleneoxy; heterocyclyl; amino; alkylamino; dialkylamino; (dialkylamino)alkyleneoxy; and, in the case of alkyl, alkenyl, alkynyl, and heterocyclyl, oxo;

10

15

R_5 is selected from the group consisting of:



20

R_6 is selected from the group consisting of =O and =S;

R_7 is C_{2-7} alkylene;

R_{8a} is selected from the group consisting of hydrogen and C_{1-4} alkyl;

R_8 is selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxyalkylenyl, alkoxyalkylenyl, arylalkylenyl, and heteroarylalkylenyl;

5 R_9 is selected from the group consisting of hydrogen and alkyl;

R_{10} is C_{3-8} alkylene;

A is selected from the group consisting of $-CH_2-$, $-O-$, $-C(O)-$, $-S(O)_{0-2}-$, and $-N(-Q_1-R_4)-$;

A' is selected from the group consisting of $-O-$, $-S(O)_{0-2}-$, $-N(-Q_1-R_4)-$, and $-CH_2-$;

10 Q_1 is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_8)-W-$, $-S(O)_2-N(R_8)-$, $-C(R_6)-O-$, $-C(R_6)-S-$, and $-C(R_6)-N(OR_9)-$;


Q_2 is selected from the group consisting of a bond, $-C(R_6)-$, $-C(R_6)-C(R_6)-$, $-S(O)_2-$, $-C(R_6)-N(R_{8a})-W-$, $-S(O)_2-N(R_{8a})-$, and $-C(R_6)-O-$;

15 V is selected from the group consisting of a bond, $-C(R_6)-$, $-O-C(R_6)-$, $-N(R_8)-C(R_6)-$, and $-S(O)_2-$;

W is selected from the group consisting of a bond, $-C(O)-$, and $-S(O)_2-$; and

a and b are independently integers from 1 to 6 with the proviso that $a + b$ is ≤ 7 ; or a pharmaceutically acceptable salt thereof.


20 5. The compound or salt of claim 4 wherein the compound is of the Formula VI:



VI

or a pharmaceutically acceptable salt thereof.

25 6. The compound or salt of claim 4 wherein the compound is of the Formula VII:




VII




or a pharmaceutically acceptable salt thereof.

7. The compound or salt of any one of claims 1 through 6 wherein n is 0.

8. The compound or salt of any one of claims 1 through 7 wherein R₁ is selected from the group consisting of -R₄, -X-R₄, -X-Y-R₄, and -X-R₅.

9. The compound or salt of any one of claims 1 through 8 wherein R₁ is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, dihydroxyalkyl, -X-Y-R₄, -X-R₅, and heterocyclalkylenyl wherein the heterocycl of the heterocyclalkylenyl group is optionally substituted by one or more alkyl groups; wherein X is alkylene; Y is -N(R₈)-C(O)-, -N(R₈)-S(O)₂-, -N(R₈)-C(R₆)-N(R₈)-,

-N(R₈)-C(R₆)-O-, -C(O)-, -S(O)₂-, or ; R₄ is alkyl, aryl, heteroaryl, arylalkylenyl, heteroarylalkylenyl, or arylalkenylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocycl, cyano, alkoxy, and dialkylamino; and R₅ is

, , or .

10. The compound or salt of the claim 9 wherein X is C₂₋₆ alkylene.

11. The compound or salt of any one of claims 1 through 10 wherein R₁ is selected from the group consisting of 2-hydroxy-2-methylpropyl, 2-methylpropyl, 2,3-

dihydroxypropyl, 4-[(methylsulfonyl)amino]butyl, 2-methyl-2-
[(methylsulfonyl)amino]propyl, 2-(acetylamino)-2-methylpropyl, 2-
{[(isopropylamino)carbonyl]amino}-2-methylpropyl,
4-{[(isopropylamino)carbonyl]amino}butyl, 4-(1,1-dioxidoisothiazolidin-2-yl)butyl,
5 tetrahydro-2*H*-pyran-4-ylmethyl, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl, 2,2-dimethyl-4-
oxopentyl, (1-hydroxycyclobutyl)methyl, (1-hydroxycyclopentyl)methyl, and (1-
hydroxycyclohexyl)methyl.

12. The compound or salt of any one of claims 1 through 7 wherein R₁ is selected from
10 the group consisting of -N(R₁')-Q₁-R₄, -D'-X₁-Y₁-R₄, and -D'-X₁-R_{5a}.

13. The compound or salt of any one of claims 1 through 12 wherein R₂ is -R₄.

14. The compound or salt of claim 13 wherein R₂ is selected from the group consisting
15 of hydrogen, alkyl, alkoxyalkylenyl, and hydroxyalkylenyl.

15. The compound or salt of claim 14 wherein R₂ is selected from the group consisting
of hydrogen, methyl, ethyl, propyl, butyl, 2-methoxyethyl, 2-hydroxyethyl, ethoxymethyl,
and hydroxymethyl.

20

16. The compound or salt of any one of claims 1 through 8 wherein R₂ is -OH, and R₁
is selected from the group consisting of pyridin-3-ylmethyl, isoxazol-5-ylmethyl, isoxazol-
3-ylmethyl, [5-(4-fluorophenyl)isoxazol-3-yl]methyl, [3-(4-fluorophenyl)isoxazol-5-
yl]methyl, tetrahydro-2*H*-pyran-4-ylmethyl, and benzyl, wherein benzyl is unsubstituted
25 or substituted by one or more substituents independently selected from the group
consisting of alkyl, alkoxy, haloalkyl, haloalkoxy, and halogen.

17. The compound or salt of any one of claims 1 through 12 wherein R₂ is -NH-Q₂-R₄.


30 18. The compound or salt of any one of claims 1 through 17 wherein R₃ is -Q-R₄.

19. The compound or salt of claim 18 wherein Q is selected from the group consisting of -C(O)-, -S(O)₂-, -C(O)-N(R₈)-, -C(O)-O-, and -S(O)₂-N(R₈)-.

20. The compound or salt of claim 18 or claim 19 wherein R₄ in -Q-R₄ is selected from the group consisting of alkyl, aryl, heteroaryl, heterocyclyl, and arylalkylenyl, wherein
 5 aryl, alkyl, and aryl in arylalkylenyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, and alkyl, and wherein heterocyclyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl and oxo.


10

21. The compound or salt of any one of claims 18, 19, and 20 wherein Q is -C(O)- or -S(O)₂-, and -R₄ is selected from the group consisting of:




15

22. The compound or salt of any one of claims 18, 19, and 20 wherein Q is -C(O)-O-, and -R₄ is selected from the group consisting of:



20

23. The compound or salt of any one of claims 1 through 17 wherein R₃ is



25

24. The compound or salt of claim 23 wherein Q is -C(O)- or -S(O)₂-, Q₁ in -Q₁-R₄ is -C(O)-, -S(O)₂-, or -C(O)-N(R₈)-, and -R₄ in -Q₁-R₄ is alkyl, aryl, heteroaryl, arylalkylenyl, or heteroarylalkylenyl, wherein alkyl, aryl, heteroaryl, or arylalkylenyl is optionally substituted by one or more substituents independently selected from the group

consisting of alkyl, halogen, haloalkyl, haloalkoxy, heterocyclyl, cyano, alkoxy, and dialkylamino.

- 5
25. The compound or salt of any one of claims 1 through 17 wherein R_3 is -Z-Ar.
26. The compound or salt of claim 25 wherein Z is alkylene.
27. The compound or salt of claim 26 wherein Z is C_{1-4} alkylene.
- 10 28. The compound or salt of any one of claims 25, 26, and 27 wherein Ar is pyridinyl, furyl, or phenyl wherein phenyl is optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, and alkyl.
- 15 29. The compound or salt of any one of claims 1 through 17 wherein R_3 is -X-Y- R_4 or -X- R_5 .
30. The compound or salt of claim 29 wherein X in R_3 is alkylene.
31. The compound or salt of claim 30 wherein X is C_{1-4} alkylene.
- 20 32. The compound or salt of any one of claims 29, 30, and 31 wherein R_3 is -X-Y- R_4 .
33. The compound or salt of any one of claims 29, 30, 31, and 32 wherein Y in the R_3 group -X-Y- R_4 is selected from the group consisting of -C(O)-, -S(O)₂-, -C(O)-O-, and
25 -C(O)-N(R_8)-.
34. The compound or salt of any one of claims 29, 30, 31, 32, and 33 wherein R_4 in the R_3 group -X-Y- R_4 is selected from the group consisting of alkyl, alkenyl, heterocyclyl, aryl, and arylalkylenyl, wherein aryl and aryl in arylalkylenyl are optionally substituted by
30 one or more substituents independently selected from the group consisting of halogen, alkoxy, alkyl, and amino, and wherein alkyl is optionally substituted by one or more


substituents independently selected from the group consisting of fluoro, alkoxy, and heterocyclyl.

35. The compound or salt of any one of claims 29, 30, 31, and 32 wherein Y in R₃ is -NH-Q₁-.

36. The compound or salt of claim 35 wherein Q₁ in -NH-Q₁- is -C(O)-, -S(O)₂-, or -C(O)-N(R₈)-, and R₄ in -NH-Q₁-R₄ is selected from the group consisting of alkyl, aryl, heteroaryl, heterocyclyl, and arylalkylenyl, wherein aryl, alkyl, and aryl in arylalkylenyl are optionally substituted by one or more substituents independently selected from the group consisting of halogen, alkoxy, and alkyl, and wherein heterocyclyl is optionally substituted by one or more substituents independently selected from the group consisting of alkyl and oxo.

37. The compound or salt of any one of claims 29, 30, and 31 wherein R₃ is -X-R₅.

38. The compound or salt of any one of claims 29, 30, 31, and 37 wherein R₅ in the R₃ group -X-R₅ is selected from the group consisting of:



39. The compound or salt of any one of claims 1 through 17 wherein R₃ is -alkylene-CH(CH₂-OH)-OH, -alkylene-CH(CH₂CH₂-OH)-OH, or -(alkylene)₀₋₁-CH(CH₂OH)₂.

40. The compound or salt of claim 39 wherein R₃ is -CH(CH₂OH)₂.

41. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of any one of claims 1 through 40 and a pharmaceutically acceptable carrier.

42. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of any one of claims 1 through 40 or the pharmaceutical composition of claim 41 to the animal.

5 43. A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of any one of claims 1 through 40 or the pharmaceutical composition of claim 41 to the animal.

10 44. A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of any one of claims 1 through 40 or the pharmaceutical composition of claim 41 to the animal.